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Transplantation
Abstract
The purpose of this study was to create time-related centile ranges that could be
used as benchmarks for evaluating and monitoring quality of life (QoL) following kidney transplantation.
QoL is commonly viewed as an important indicator of successful outcomes in chronic disease including
kidney transplantation. Despite extensive research documenting the value of QoL, routine measurement
of QoL outcomes in clinical practice as a means of patient evaluation to augment clinical care has not
been widely accepted. Lack of benchmarks for interpreting QoL scores may contribute to the reluctance
to incorporate QoL measures into clinical care. The research question and study aim were: Do QoL
outcomes differ for patients by gender and race at four separate time intervals following renal
transplantation? Based on this analysis which demographic groups or combination of groups would be
required to accurately represent QoL outcomes through time-related centile ranges?
A convenience sample was drawn from the surveys housed by the national Patient
Outcomes Registry for Transplant Effects on Life (PORTEL). To be included in the
study, surveys must have been completed by Caucasian or African American recipients of one kidney
transplantation who were between 18 and 65 years of age and who were greater than 14 days posttransplant. SF-12 and Memphis Survey scores were extracted as the QoL measures for creation of timerelated centile ranges. Data were analyzed using nonparametric statistical methods. Time-related centile
ranges were constructed depicting the 5th through the 95th percentile scores on the QoL outcome
measures.
The analysis included 943 surveys bracketed into four time groups, less than 4
months, 4 to 19 months, 19-36 months and greater that 36 months from transplantation. Kruskal-Wallis
analyses demonstrated a strong degree of homogeneity among racial and gender groups with only 2 of
16 QoL outcome measures differing significantly; SF-12 PCS scores at 19-36 months and Memphis
Frequency scores at less than 4 months. Variation in means across the groups was small and the centile
ranges were large leading to the conclusion that negligible clinical differences exist for these QoL
outcomes by racial and gender subgroups in this sample. Therefore, one time-related centile range was
constructed for each QoL outcome measure for this cohort of kidney transplant recipients
which will be graphically presented.
These time-related centile ranges have immediate clinical utility as a tool for
educating patients regarding QoL expectations and for monitoring post transplant QoL outcomes. They
can also provide a means for transplant recipients to compare their QoL to a reference range that is
derived from a like population and serve as a catalyst for discussion regarding interventions to enhance
QoL for kidney transplant recipients.

Document Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Program
Nursing

Research Advisor
Donna Hathaway, Ph.D.

Keywords
Renal transplant, Quality of life, centile ranges, benchmarks

Subject Categories
Diseases | Medicine and Health Sciences | Nursing

This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/90

TIME-RELATED CENTILE RANGES FOR QUALITY OF LIFE OUTCOMES IN
RENAL TRANSPLANTATION

A Dissertation
Presented for
The Graduate Studies Council
The University of Tennessee
Health Science Center

In Partial Fulfillment
Of the Requirements for the Degree
Doctor of Philosophy
From The University of Tennessee

By
Katy Garth
December 2008

Copyright © 2008 by Katy Garth
All rights reserved

ii

ACKNOWLEDGEMENTS
I would like to acknowledge the help and support provided by a number of
individuals and groups in the completion of this dissertation. First I would like to thank
my committee for sharing their expertise and for their encouragement. I would like to
acknowledge the contributions of Quorum Consulting in providing the data used in this
study, in particular Kuo Tong, Founder and CEO and Andrew Layton, Director,
Healthcare Data and Applications for assistance with study design and data management.
I want to thank Leslie Evans for her contributing her expertise in graphic arts that led to
the design of the time-related centile ranges developed in this dissertation. Finally, I want
to thank my family for their ongoing support in all of my academic efforts.

iii

ABSTRACT
The purpose of this study was to create time-related centile ranges that could be
used as benchmarks for evaluating and monitoring quality of life (QoL) following kidney
transplantation. QoL is commonly viewed as an important indicator of successful
outcomes in chronic disease including kidney transplantation. Despite extensive research
documenting the value of QoL, routine measurement of QoL outcomes in clinical
practice as a means of patient evaluation to augment clinical care has not been widely
accepted. Lack of benchmarks for interpreting QoL scores may contribute to the
reluctance to incorporate QoL measures into clinical care. The research question and
study aim were: Do QoL outcomes differ for patients by gender and race at four separate
time intervals following renal transplantation? Based on this analysis which demographic
groups or combination of groups would be required to accurately represent QoL
outcomes through time-related centile ranges?
A convenience sample was drawn from the surveys housed by the national Patient
Outcomes Registry for Transplant Effects on Life (PORTEL). To be included in the
study, surveys must have been completed by Caucasian or African American recipients
of one kidney transplantation who were between 18 and 65 years of age and who were
greater than 14 days post-transplant. SF-12 and Memphis Survey scores were extracted as
the QoL measures for creation of time-related centile ranges. Data were analyzed using
nonparametric statistical methods. Time-related centile ranges were constructed depicting
the 5th through the 95th percentile scores on the QoL outcome measures.
The analysis included 943 surveys bracketed into four time groups, less than 4
months, 4 to 19 months, 19-36 months and greater that 36 months from transplantation.
Kruskal-Wallis analyses demonstrated a strong degree of homogeneity among racial and
gender groups with only 2 of 16 QoL outcome measures differing significantly; SF-12
PCS scores at 19-36 months and Memphis Frequency scores at less than 4 months.
Variation in means across the groups was small and the centile ranges were large leading
to the conclusion that negligible clinical differences exist for these QoL outcomes by
racial and gender subgroups in this sample. Therefore, one time-related centile range was
constructed for each QoL outcome measure for this cohort of kidney transplant recipients
which will be graphically presented.
These time-related centile ranges have immediate clinical utility as a tool for
educating patients regarding QoL expectations and for monitoring post transplant QoL
outcomes. They can also provide a means for transplant recipients to compare their QoL
to a reference range that is derived from a like population and serve as a catalyst for
discussion regarding interventions to enhance QoL for kidney transplant recipients.
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CHAPTER 1. INTRODUCTION
Extraordinary advancements in science achieved in the 20th century have changed
the view of and expectations for health, disease, and treatment of disease. New treatments
and technology allow individuals to survive for many years with conditions that
previously would have been fatal such as end-stage renal disease (ESRD). Renal
replacement therapy (RRT), peritoneal dialysis or hemodialysis; and transplantation have
led to long term survival for individuals with ESRD. Kidney transplantation has not only
prolonged life, but in addition it has been shown to improve quality of life (QoL) for
many individuals as well (Dew et al., 1997; Ogutmen et al., 2006; Overbeck et al., 2005).
However, while transplantation and the immunosuppressant therapy that is required to
prevent rejection make survival possible with a better QoL, patients continue to have
health related issues following transplantation. Ongoing treatments, including intensive
medication regimens, often lead to compromises in health or functional ability that can
impact QoL (Winsett et al., 2004). With improved patient and graft survival, attention to,
and evaluation of, QoL in transplant recipients is an important part of ongoing care, as
well as the assessment of graft and patient survival.
Problem Statement
As individuals contemplate whether they should undergo a treatment such as
organ transplantation in order to improve their health care outcomes, they seek
information regarding the typical recovery pattern displayed by individuals who are like
them. Health care providers also look at patterns of response in groups of patients to
recommend treatment plans based on the risks and benefits of the treatments in question.
The knowledge gained through examining patterns of recovery can assist the patient in
determining whether their progress or their health status is typical for an individual in a
similar situation at a particular point in time. This type of information is often a key
factor in making initial treatment decisions as well as in the planning of care to facilitate
recovery. QoL has become an important outcome used by patients and health care
providers alike for evaluating the effectiveness of treatment regimens for chronic disease
(Carr, Gibson, & Robinson, 2001; Sullivan, 2003). Understanding QoL outcomes may be
particularly important for the individual contemplating kidney transplantation since in
many cases alternative therapy (i.e. hemodialysis or peritoneal dialysis) is available. The
choice to undergo transplantation is seen as a means to improve QoL as opposed to the
only treatment means available for survival. Although kidney transplantation has been
shown in multiple studies to improve QoL (Cameron, Whiteside, Katz, & Devins, 2000;
Dew et al., 1997), individuals who have undergone kidney transplantation want to know
how their post-transplantation quality of life compares to others at the same point in their
recovery; yet this information is not available.
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Purpose of the Study
The overwhelming number of articles published each year that focus on QoL is
testimony to the growing interest in the QoL associated with the treatment of chronic
disease. In spite of the tremendous interest in QoL in the field of kidney transplantation
and the numerous reports documenting improvement in QoL following transplantation,
construction of a trajectory that maps the typical progression in QoL after transplantation
has not been reported. Therefore, the purpose of this study will be to construct timerelated centile ranges that depict the progressive changes in QoL that occur following
kidney transplantation.
Study Aims
This descriptive study established time-related centile reference ranges to report
QoL outcomes in such a way that clinicians and patients can evaluate the QoL of
individuals and compare it with others who have similar demographic characteristics. The
time-related centile ranges were constructed from data collected through the Patient
Outcomes Registry for Transplant Effects on Life (PORTEL), which conducted surveys
of transplant recipients from 2000-2005. The QoL outcome measures drawn from the
PORTEL Survey for creation of time-related centile ranges included the physical and
mental component summary scores from the 12-Item Short Form Health Survey (SF-12)
and the frequency and severity scores from the Memphis Survey, a measure of
immunosuppressant related side effects. The study progressed in two stages guided by the
research question and a study aim. Stage 1 was directed by the research question and
identified how the study population should be grouped to address the study aim during
stage 2 of the study which involved generation of the centile ranges. The research
question (1) and study aim (2) are as follows:
1. Do QoL outcomes differ within groups of patients categorized by gender and
race? If so then:
a) Do the QoL outcome measures for patients grouped by gender and
race differ at four specific time intervals following transplantation?
b) Which of the variables or combination of variables (gender and race)
identify cohorts of patients most appropriate for creation of timerelated centile ranges used to illustrate QoL outcomes?
2. Individual time-related centile ranges were established for scores on the SF-12
and the Memphis Survey for each patient group identified in stage 1. The QoL
measures included separate scores for the:
a) SF-12:
i. Physical Component Summary (PCS)
ii. Mental Component Summary (MCS)
b) Memphis Survey scores:
i. Frequency score how often side effects occur)
ii. Severity score (level of distress caused by the side effects)
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Background and Significance
The health related literature is replete with references to QoL. Though the concept
is has been defined in many ways the definitions are often ambiguous (Meeberg, 1993).
According to Hathaway, et al. (2003a), QoL is “broadly accepted to be a
multidimensional construct that represents an individual’s perception of his or her health,
happiness, and general well-being at any given period of time” (p. 1). Other authors have
differentiated the general term QoL from the concept of health related QoL including the
physical, psychological, and social domains of health in the definition (Pinson et al.,
2000; Testa & Simonson, 1996). QoL has also been defined in such a way that it reflects
the individual’s functional ability, their perception of their health and well being, and
their emotional health (Cetingok, Winsett, & Hathaway, 2004). Many factors beyond
disease influence QoL including overall health and social status (Cetingok et al., 2004).
There has been a shift in the emphasis of the health care industry from focusing
primarily on curing disease to focusing on controlling disease while enhancing QoL and
utilizing QoL as a measure of success in the treatment of disease (Yildirim, 2006). In the
past, the goal of health care as an industry was on treatment to cure disease, or palliative
care when curative treatment was not an option. Advances in therapeutics have led to
changes in the delivery of health care, and diseases that would have once been fatal, are
now regarded as chronic conditions with patients leading long and productive lives. As a
result of this transition, the goal of treatment for patients with chronic illness is
increasingly aimed at controlling disease and maintaining QoL.
Side effects associated with treatment for both acute and chronic disease present
challenges for health care providers as well as the patient. As opposed to palliating
symptoms of disease, interventions often involve palliation of the side effects of the
treatment regimen (Holley, 2007). Assessment of the QoL that a patient experiences on a
day to day basis, as they live with their disease and the treatment of their disease, can
guide health care providers in recognizing patient’s needs and formulating a plan of care
to meet those needs. The use of QoL outcome measurements in nontransplantation
clinical settings have been shown to enhance communication between the patient and the
health care provider about QoL issues such as social functioning or symptoms that might
be otherwise left unaddressed (Detmar, Muller, Schornagel, Wever, & Aaronson, 2002).
An individual’s expectation of their QoL at a given time in life or in relation to a
given illness can influence the perception of their QoL (Carr et al., 2001). It is in this
context that patients who are contemplating transplantation; or who are post
transplantation seek information regarding the QoL they can anticipate or how their
actual QoL compares with that of other transplant recipients. Studies have examined both
short- and long-term QoL post transplantation, and several instruments have been
developed and validated to measure QoL. However, routine use of QoL outcome
measurement in the clinical setting has not been widely implemented (Higginson & Carr,
2001). There are no established norms for QoL post kidney transplantation that can be
used for providing education or for evaluating recovery. Benchmarks that reflect the QoL
of kidney transplant recipients could provide an additional tool in the clinical
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armamentarium to augment post transplantation care. These benchmarks would provide
normative data for use in educating patients regarding QoL post transplantation and help
reconcile their post-transplantation QoL with those reported by other transplant
recipients.
This study creates time-related centile ranges from QoL data collected through the
Patient Outcomes Registry for Transplant Effects on Life (PORTEL) that could be used
in the clinical setting as benchmarks for evaluation of QoL outcomes of individual
patients. These ranges provide clinical tools for education, evaluation, and identification
of individuals at risk for poor QoL and enabling pre-emptive interventions to improve
their QoL outcomes.
PORTEL Registry
The Patient Outcomes Registry for Transplant Effects on Life (PORTEL) is a
national data registry that was established by Fujisawa Pharmaceuticals in 2000 to
document various aspects of the QoL of solid organ transplant recipients. The goals of
the PORTEL registry included the collection of longitudinal data following solid organ
transplantation, documenting of the side effects of immunosuppressive therapy, and
identifying predictors of QoL post transplantation with the intent of using the data to
establish norms for QoL following transplantation (Hathaway, Winsett, Prendergast, &
Subaiya, 2003). The PORTEL survey instrument was based on a QoL framework
composed of 5 interrelated domains that included QoL, health and social factors and,
major health and major life events (Hathaway, et al., 2003b) that influence both the
physical and psychosocial aspects of QoL. This framework provides direction for the
examination of QoL and exploration of the concept in this population.
The PORTEL Registry Four-Cornered Framework
The QoL that an individual experiences is related to health and social factors, as
well as major health and life events. “Factors” (health and social) are conceptualized to
reflect those circumstances or conditions that, though they may fluctuate to some degree
over time, remain relatively stable. As these factors reach an optimal state and stabilize,
post transplantation QoL is enhanced. “Events” (health and life) are conceptualized to
reflect more acute and transient circumstances or conditions that may negatively impact
QoL. These “events” and “factors” interact with one another to moderate each of their
relative influences on QoL, which in turn influences adaptation to and coping with the
health and social factors and major life and major health events that are a part of the
transplant recipient’s life (Hathaway et al., 2003b).
Health factors include comorbidities that were present prior to transplantation, or
developed subsequent to transplantation, requiring ongoing therapy; or that occured
following transplantation as a result of side effects from immunosuppressant therapy
(Hathaway, et al., 2003b). Social factors include situations and events that define an
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individual’s social environment including the financial resources available to the
individual, their health care coverage and the social support available to the transplant
recipient (Hathaway et al., 2003b). Health and social factors influence QoL, as well as
each other, and the health and life events that the individual encounters.
While health factors and social factors may determine an individual’s day to day
routine, the ability to cope with them is effected by the major health and life events that
occur episodically throughout life. Major health events, according to Hathaway, et al.
(2003b), may be related to a major change in the individual’s health, such as a rejection
episode. A major health event could also be a fracture secondary to osteoporosis related
to immunosuppressant therapy or a cardiac event. Major health events could be life
threatening, a threat to the function of the graft, or a threat to the individual’s ability to
function or live independently.
Major life events, as with major health events, are those events which also occur
periodically, disrupting the established routine of the individual or the family (Hathaway,
et al., 2003b). A major life event as defined in the PORTEL framework may be a divorce,
death in the family, or loss of a job. Major life and health events influence the perception
of QoL and health and social factors.
Time-Related Centile Ranges
Reference ranges, often referred to as normal ranges, have long been used in health
care to evaluate the health status of individual patients, on some specific parameter, by
comparing a variable to a standard for that variable established from a healthy population.
The range of normal for a given variable is typically defined as the range of values for
that variable in the population of interest that fall between the 2.5th and the 97.5th
percentile (Griffiths, Iles, Koduah, & Nix, 2004). A basic assumption must be that the
population from which the reference range is derived is representative of “typical”
individuals and therefore the values for that variable in that population are considered to
be the normal range. The variables that are reported in a reference range are often
affected by other characteristics of the representative population (Wright & Royston,
1997). When this is the case, a single reference range is inadequate. Time is an example
of such a covariate that can affect the outcome of interest (Cole & Green, 1992). The age
of the individual at the time of measurement or the amount of time that has elapsed since
an event has occurred can have a significant influence on the mean and standard
deviation of a given measurement, therefore reference intervals are commonly
established with age or time as a covariate (Royston & Wright, 1998). A common
example of a reference range established to follow change in a variable over time is the
series of ranges that have been established to monitor the rate of human growth. Growth
charts are routinely used by health care providers to evaluate the growth of children over
time. These charts are used to identify those children who are not growing at the
anticipated rate or who have not achieved the desired height or weight for their age. The
time-related centile ranges for QoL outcomes of kidney transplant recipients proposed in
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this study could be used in a similar manner to follow QoL outcomes over time as well
asevaluating QoL at a particular point in time.
Summary
The PORTEL Four-corner framework provided the conceptual underpinnings for
this investigation. It provided direction for the consideration of QoL outcomes, the
factors and events that influence these outcomes, and potential avenues for interventions
to enhance QoL when it is less than what is perceived to be “normal.” The PORTEL
framework was merged with the analytical perspective of time-related centile ranges to
provide a mechanism by which to establish a normal range for QoL outcomes
measurements for transplant recipients, enabling patients and providers to make informed
decisions regarding treatment, including initiation of new disease management therapy or
health promotion to improve QoL (Figure 1.1). QoL can change over time as the factors
and events that influence it change, therefore, continued follow up with periodic
evaluation is important for long term well being.
Operational Definitions
Quality of Life
Defining QoL requires integration of objective and subjective domains (Testa &
Simonson, 1996) that include objective measurements of the individual’s physical health,
their perception of their health, and their overall sense of well being. Health and life
events or factors effect the individual’s perception of their QoL as well as their ability to
function. For purposes of this study, QoL is considered to be a multidimensional concept
reflected by the following domains and measures.
Mental QoL. Mental QoL refers to the individual’s perception of their well-being
and ability to function in their social roles as measured by the MCS Score of the SF-12.
The SF-12 includes questions concerning vitality, social functioning, role-emotional
functioning, and mental health (Ware, Kosinski, & Keller, 1996).
Physical QoL. Physical quality of life includes the individual’s objective health
indicators as well as their perception of their physical health. The PCS score on the SF12, was used as the measure of physical QoL, and incorporates physical functioning, role
functioning, pain, and general health (Ware et al., 1996).
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Figure 1.1. Conceptual Model of QoL Domains as Defined by the PORTEL Framework
with the Integration of QoL Outcome Measurement and Time-Related Centile Ranges.
Adapted with permission. Hathaway, D., Barr, M. L., Ghobrial, R. M., Rodrigue, J.,
Bogner, S., Prendergast, M. M., et al. (2003b). The PORTEL registry: Overview and
selected findings. Progress in Transplantation, Supplement, 3-13.
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Immunosuppressant Side Effects
The multiple side effects that can result from immunosuppressive therapy have a
marked impact on QoL and are defined by, and measured, using the Memphis Survey.
This is a disease specific tool designed to assess the impact of side effects on QoL based
on their frequency and severity; specifically related to emotional burden, life/role
responsibilities, mobility, gastrointestinal distress, and miscellaneous side effects
including gingival hypertrophy, increased hunger, somnolence, weight gain, increased
hair growth, infections, trembling hands, high blood pressure, easy bruising, decreased
libido and sexual performance (Winsett et al., 2004).
Time-Related Centile Range
Time-related centile ranges plot a value for a variable against a covariate such as
time. The ranges established provide an estimation of the value of a variable that the
majority of a population exhibit at a given time and is considered to be a norm for the
population. Time-related centile ranges have been used for evaluation of a patient’s
current status or to monitor changes in the variable over time. In this study the covariate
of interest was the time that has elapsed since kidney transplantation and the variable of
interest was QoL as measured by the SF-12 and the Memphis Survey. Values from these
instruments were used to create time-related centile ranges that provided benchmarks for
QoL following kidney transplantation.
Assumptions
The framework of this study was grounded on the following assumptions:
1. Improvement in QoL is desired by individuals.
2. Expected QoL outcomes play a key role in decisions regarding whether to
undergo kidney transplantation or continue with alternative methods of kidney
replacement therapy.
3. Patients and providers use normal values to benchmark patient progress.
4. QoL is multi-dimensional composed of physical and mental functions that
influence and are influenced by health and social factors and major life and
health events.
5. QoL is dynamic and can be influenced positively and negatively by external
conditions and circumstances, some of which are modifiable or can be
accommodated.
6. The survey was self-administered and returned to the registry via mail or
internet, therefore an assumption related to the nature of the study was that the
survey was completed by the individual and not a family member or friend.

8

Limitations
The following limitations were considered during the conduct of, and in
interpreting the outcomes of, this study:
1. QoL is an individually perceived phenomenon and may or may not reflect the
actual health and well being of the individual. However, by definition QoL is
the individual’s self perception, therefore, regardless of how one compares
their status with a “normal” benchmark, it is the patient’s perception of their
QoL that determines successful outcomes.
2. The patient’s desire to be “normal” as they have previously defined it may not
be a realistic, or achievable, goal given the complexity of personal, social, &
health factors and events that surround kidney transplantation. Regardless,
time-related centile ranges provide valuable comparison data. This vast array
of potential combinations of personal, social and health factors and events
precludes establishing centile ranges for all the conceivable combinations,
therefore application and use must be done with caution.
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CHAPTER 2. LITERATURE REVIEW
QoL has been well established as an important concept in society as well as for
health care. Pais-Riberio (2004) stated that measurement of QoL dates to President
Eisenhower’s Commission on National Goals published in 1960. There have been
literally hundreds of articles from all over the world published on QoL in kidney
transplantation alone. It is well accepted that kidney transplantation has led to improved
QoL as compared to hemodialysis or peritoneal dialysis (Dew, et al., 1997), however
little has been done that translates that knowledge for use in direct patient care. Tools
providing benchmarks for comparison of the QoL outcomes of an individual patient to a
large population of kidney transplant recipients would augment the interpretation of QoL
measures in the clinical setting and enhance patient assessment. The purpose this
manuscript is to discuss the elements that lead toward the next step in addressing QoL of
kidney transplant recipients, that is bringing the measurement of QoL to the practice
arena.
Chronic disease, including renal disease, presents special challenges for patients
in attaining their desired QoL and for health care providers as they attempt to measure
and monitor their patients’ QoL. Yet the desire to address these challenges grows as
patients and providers seek interventions to improve QoL and methods by which they can
document the success of these interventions. Much has been learned from numerous
clinical trials about how to measure QoL at various stages of disease and from different
patient populations. However, little has been done that addresses how QoL assessments
could be used to evaluate the individual patient’s progress, to identify patients who could
benefit from interventions designed to improve QoL, to help patients evaluate their own
QoL in relationship to others with similar characteristics, or to inform patients and
providers about reasonable QOL expectations on an individual basis. Using QoL
measures to inform patient care brings QoL assessment from the research arena to the
bedside. This paper will discuss the changes in chronic illness, particularly renal disease,
that have made attention to the assessment of QoL a primary focus for patient care,
present an overview of findings from extant research, and make recommendations for the
practical application of transplantation-related QOL knowledge that has accumulated
over the last several decades.
The Changing Face of Chronic Illness
The incidence of chronic disease has increased over the course of the last century.
The primary cause of death at the beginning of the last century was infectious disease but
by the beginning of the 21st century the leading cause of death had changed and chronic
diseases such as heart disease, stroke, and cancer had become the most common causes of
death (Healthy people, 2001). Newer and more effective treatment modalities for both
acute and chronic illnesses have led to long term survival for many individuals with
conditions that would have previously been fatal, contributing to the increase in the
number of individuals who are living with chronic conditions (Ironside et al., 2003). With
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this increase in the prevalence of chronic and often disabling conditions, the focus of
health care has expanded to encompass not only quantity but quality of life with attention
to rehabilitation and health promotion for individuals with disabling disease as a primary
goal (Brandt & Pope, 1997).
Chronic conditions, by definition, are of long duration if not life-long (Bury,
1991). The goal of treatment is not to achieve cure of disease, but rather control of the
progression and symptoms of disease. Improved coping and enhancement or maintenance
of function becomes the goals in planning and implementing care (Cluff, 1981). With this
shift from cure of disease to disease control as the focus of therapy, QoL becomes a
common factor that brings together a variety of issues that influence an individual’s wellbeing and can be used to determine the effectiveness of therapy (Musschenga, 1997).
Thus, QoL and the impact of disease and treatment on QoL, have been recognized as
priorities in planning and implementing health care (Moons, 2004).
Quality of Life: The Key Outcome in Chronic Disease
Incorporation of patient centered QoL outcomes as desirable indicators of the
efficacy of health care is causing a paradigmatic shift, where the focus of care and care
planning is the patient not the disease (Carr & Higginson, 2001). This paradigm shift can
have particular significance for the patient who is dealing with a long-term chronic
condition, and the chosen or required treatment, as well as the disease itself, can impact
QoL. Moreover, because the patient is dealing with a long-term condition their
relationship with the health care community will be ongoing. The diagnosis of a chronic
condition can have a dramatic impact on an individual’s life and role function. The
manner in which they adapt to and cope with chronic illness will influence the way in
which an individual lives their life and hence perceives the quality of the life they are
living (Corbin & Strauss, 1992)
The attributes that define QoL for a person or family are varied, steeped in their
values and cultural traditions. The individual’s perception of QoL is determined by the
interaction of their expectation of what QoL should be and their experience related to
wellness, illness, and functional ability (Carr, Gibson, & Robinson, 2001). Two patients
in similar settings with similar conditions may perceive their QoL differently depending
on their life experiences and expectations regarding QoL, illness, and the interaction of
the two. Studies have attempted to describe patients’ perceptions of their diseases and
implications for QoL and have demonstrated that attitudes toward chronic illness and the
perceptions of chronic illness have changed over time. Thorne and Patterson (1998), in a
meta-study examining the roles of clients with chronic disease through two decades of
qualitative research found that the perceptions of patients had evolved from a
predominantly negative theme of suffering and loss during the 1980’s to a more positive
perception with themes such as reshaping or reconstituting self, finding meaning, and
regaining control. They postulate that this transition in perception may in part contribute
to a shift in the viewpoints of health care providers and patients from one of the client as
patient to the client as partner. Assuming a partnership role in planning care,
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reconstituting, reshaping, and regaining control implies an active role taken by patients in
disease and lifestyle management, and includes seeking information and self evaluation
as integral to that role. QoL outcome measures used in the clinical setting as assessment
tools for patients and providers can be a beneficial adjunct as patients evaluate their QoL
and how it compares with others.
Trajectories in Chronic Illness and Kidney Transplantation
Corbin and Strauss (1992) in their nursing model for chronic illness conceptualize
the course of chronic illness as a multiphase trajectory that changes over time. The
trajectory of chronic illness, and the associated QoL changes that may follow when one is
diagnosed with a chronic illness, reflect not only the physiologic qualities of the illness
but all aspects of the patient’s life and that of their family (Corbin & Strauss, 1992). The
experience of chronic illness requires a shift in expectation from the anticipated preillness life trajectory to one of life with a chronic illness that incorporates the changes
that occur as a result of the chronic illness or accompanying disability. Within this shift is
the added reality that a chronic illness is not a static but a dynamic state, influenced by
multiple aspects of life and changing with time and disease progression (Joachim &
Acorn, 2000). The ultimate goal in addressing the changing trajectory of a chronic illness
is improving or maintaining the QoL of the patient and family. Chronic illness
trajectories are individual; however, certain aspects of the trajectory can be anticipated
and guidance can be provided that influences the trajectory at particular points in time
(Corbin & Strauss, 1992). Ponton et al., (2001) identified variation in QoL outcome
measurements after kidney transplantation over time. QoL in the immediate post
transplantation period was rated as high, with a decrease in perceived QoL during the 7 to
36 month period after transplantation; followed by improvement as the time from
transplantation subsequently increased. The variation in QoL may be related to social or
health factors that intervene over time, including adjustment to the reality that post
transplantation, patients continue to have health issues consisting of medication side
effects, complications, and psychosocial issues (Ponton et al., 2001). Assessment of QoL
in chronic illness and the changes in QoL that occur is an ongoing process that requires
continued attention and follow-up in order to identify points at which intervention to
improve QoL might be beneficial.
The desire to be normal or to achieve normalcy in life in the face of chronic
disease is associated with QoL by patients in studies focusing on coping and adaptation in
chronic illness (Bradford, 1991; McGrath, Paton, & Huff, 2005; Obrecht, Gallo, & Knafl,
1992; Snethen, Broome, Bartels, & Warady, 2001). Chronic illness, including kidney
transplantation may require that an individual redefine what they consider to be normal in
terms of their QoL as they adapt to their individual chronic illness trajectory. Failure to
make such a redefinition can lead to feelings of ongoing frustration and failure (Baines,
Joseph, & Jindal, 2002). Redefining normal requires that the individual reevaluate their
potential, and develop an understanding of the limitations that may become challenges in
adapting to life following kidney transplantation. Benchmarks that establish references
for QoL following kidney transplantation may help transplant recipients in the transition
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to a new normal by reframing their pre-illness expectations for QoL with a more realistic
view of their capabilities. Comparison of QoL with that of other transplant recipients to
determine whether their QoL is comparable to, better than, or worse than the QoL that
other transplant recipients are experiencing would provide a reference point for
evaluating their current status. Support groups provide a similar function and have been
shown to relieve some of the anxiety associated with chronic illness when individuals
find that their feelings and experiences are not unique to themselves but are shared by
others and are a product of their situation (Mechanic, 1977). Seeking information,
whether it is from health care providers or others who have had the same or similar
experiences, aides in coping with and in adaptation to chronic disease (Craig & Edwards,
1983).
Defining Quality of Life
Although, the importance of QoL for individuals in evaluating health care
outcomes is well established, a widely accepted definition of QoL has been elusive
making agreement as to how it should be measured difficult (Haas, 1999; Meeberg,
1993). QoL is generally viewed as a multidimensional term representing both subjective
and objective domains (Testa & Simonson, 1996). The general concept of QoL has been
differentiated from that of health related QoL with physical, psychological, and social
domains of health included in the definition (Pinson et al., 2000). QoL has also been
defined in such a way that it reflects the individual’s functional ability, health and well
being, and psycho-emotional health (Cetingok, Winsett, & Hathaway, 2004). Many
factors beyond the impact of disease influence QoL including overall health status and
social status (Cetingok et al., 2004).
The developers of the Patient Outcomes Registry for Transplant Effects on Life
(PORTEL) have developed a framework for describing QoL following solid organ
transplantation which includes 5 separate but interrelated domains (Hathaway et al.,
2003b). The domains include health and social factors, major life and health events, and
QoL. Health factors are those health related issues that the transplant recipient deals with
on a daily basis, such as the quality of organ function, co-morbidity that can lead to
disability including diabetes or osteoporosis, side effects of immunosuppressant agents,
or health behaviors that can promote or impair health. Social factors are the daily issues
that shape social functioning, such as, economic support, health care coverage, or
available social support. Major life and major health events are episodic in nature, but can
have a significant effect on QoL and daily functioning. Major life events could include
loss of a job, death of a family member, a marriage or divorce in the family. Major health
events could include graft loss, a serious infection or other adverse event, or
hospitalization. The fifth domain in this model is QoL. While QoL can be viewed as a
separate entity, it is influenced by, and influences the other four domains (Hathaway et
al., 2003b). Figure 1.1 depicts a model adapted from the PORTEL QoL framework that
incorporates the use of outcomes based on the original framework as benchmarks for
comparison of the patient’s QoL with that of others from a similar comparison group.
Comparing one’s QoL with a similar group can be reassuring as transplant recipients

13

recognize that their QoL is similar to, or exceeds, standard benchmarks. Use of
benchmarks can also identify individuals who, with intervention, could experience
enhanced QoL. The dynamic nature of QoL can also be captured when QoL is
reevaluated over time to monitor a patient’s progress. With improved patient and graft
survival following kidney transplantation, long term follow-up will require continued
reassessment of QoL outcomes as aging influences health and social factors, and life and
health events occur.
Quality of Life in Kidney Transplantation
Many studies have demonstrated that kidney transplantation improves QoL
compared to hemodialysis or peritoneal dialysis (Fujisawa et al., 2000; Lazzaretti,
Carvalho, Mulinari, & Rasia, 2004; Molzahn, 1991; Niu & Li, 2005; Ogutmen et al.,
2006; Ostrowski, Wesolowski, Makar, & Bohatyrewicz, 2000; Overbeck et al., 2005).
Liem, Bosch, Arends, Heijunbrok-Kal & Hunink (2007) in a meta-analyses of 52 studies
that used the SF-36 to compare the QoL of transplantation, hemodialysis, and peritoneal
dialysis patients, found that following kidney transplantation, patients had better QoL
than patients receiving hemodialysis or peritoneal dialysis as renal replacement therapy.
While the majority of studies reported that kidney transplantation improved QoL, there
have also been studies which found no differences in QoL scores between
transplantation, hemodialysis, and peritoneal dialysis patients (Sayin, Mutluay, & Sindel,
2007).
When QoL post transplantation is compared to that of the general population the
results have been mixed. QoL after kidney transplantation has been reported as similar to
the QoL of the general population on subjective indicators including role performance,
social functioning, role limitations due to emotional function, and mental health (Evans et
al., 1985; Neipp et al., 2006; Rebollo et al., 2000). In other studies, QoL following kidney
transplantation was improved over other means of kidney replacement therapy but it did
not equal that of the general population (Dew et al., 1997; Overbeck et al., 2005). Older
transplant recipients, over 55 years of age, have scored higher on general health
perception than younger recipients, possibly because older patients are better able to cope
with changes and limitations that occur with age (Noohi, Karami, Lorgard-Dezfuli-Nejad,
Najafi, & Saadat, 2007). With this variation in mind, benchmarks specific to QoL post
kidney transplantation would provide more accurate and realistic comparisons for
patients and health care providers to use in assessing QoL than benchmarks from general
population data.
Predictors of Quality of Life in Kidney Transplantation
While the majority of studies have found that the QoL of transplant recipients
overall is superior to the QoL of patients receiving other types of renal replacement
therapy, there are subgroups of transplant recipients who have not experienced
improvement in QoL following transplantation. In an attempt to identify those individuals
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at risk for poorer QoL several studies have identified various health and social factors
that are predictive of QoL post kidney transplantation. Rosenberger et al. (2006) used the
term perceived health status (PHS) in lieu of QoL in a study designed to explore the
predictors of PHS. They found that the predictors of PHS changed over time, with social
support and lower creatinine predictive of higher PHS in younger patients, and fewer
hospitalizations and absence of diabetes mellitus predictive of higher PHS in older
patients. Lower stress related to adverse effects was shown to predict PHS across all
groups. Following transplantation, side effects of immunosuppressant therapy can replace
the symptoms associated with chronic renal failure as a source of patient distress that
compromises QoL (Habwe, 2006). Khedmat et. al (2007) found poorer QoL to be
associated with lower education levels, being single or widowed, and the presence of
diabetes or hypertension. Morbidity during the first six months post transplantation (as
reflected by the number of days hospitalized), employment, and social support were
identified as predictors of decreased QoL by Hathaway, et al. (1998). Employment after
transplantation, viewed as a measure of returning to social functioning, has been
correlated with better QoL (Matas et al., 2002; Matas et al., 1996). Neipp et al. (2006)
also found social factors, including employment and social support to be an important
predictor of better QoL for transplant recipients. The inter-relationships among various
predictors of post transplantation QoL is supported by findings that demonstrate that the
presence of comorbidities, the type of transplantation (cadaveric or living donor), age and
time since transplantation are correlated with participation in social activities such as
employment, education, and performance of household tasks (van der Mei et al., 2006);
both are sets of variables which have been found to be associated with post
transplantation QoL as noted above.
QoL in end stage renal disease has been studied for decades. It has been clearly
shown that kidney transplantation improves Qol for many patients, but not all, and the
desire for better QoL drives the decision for many to undergo kidney transplantation
(Shah et al., 2006). It is also apparent that there is variability in QoL outcomes and that
QoL appears to have some degree of change over time following transplantation (Ponton
et al., 2001). In spite of the intense interest in QoL and in measurement of QoL, it has
been primarily a tool used in the research setting and has not been readily translated into
the clinical setting for use in patient evaluation (Higginson & Carr, 2001). The variability
in QoL outcomes and the many health and social factors that have been identified as
predictors of QoL imply that assessment of the perceived QoL of kidney transplant
recipients in the clinical setting would be beneficial in identifying those patients at risk
for less than optimal QoL.
Quality of Life Measurement as a Tool in the Clinical Setting
There is general agreement that discussion of QoL between patients and health
care providers is beneficial, however few studies have demonstrated that measuring QoL
outcomes change clinical decision making or the patient’s clinical outcomes
(Espallargues, Valderas, & Alonso, 2000; Greenhalgh, Long, & Flynn, 2005, Levine &
Ganz, 2002). Measuring QoL in routine practice has, however, been demonstrated to
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increase communication between patients and providers (Detmar, Muller, Schornagel,
Wever, & Aaronson, 2002) leading to increased discussion of nonspecific symptoms and
better QoL and emotional functioning for patients without prolonging the patient
encounters (Velikova et al., 2004). Although most studies using QoL instruments to
assess patient outcomes did not find a change in the clinical decision making process;
increased communication was reported to be benficial in patient care. Higginson & Carr
(2001) cite five potential uses for QoL measures in the clinical setting directly related to
clinical care or the evaluation of care; including prioritizing problems, facilitating
communication, screening for potential problems, identifying preferences of patients,
monitoring changes or responses to treatments, and training new staff. While QoL
measures do not substitute for physiologic evaluation of disease; they do capture the
personal and social context of the patient and put the patient at the forefront of the
encounter.
Detmar, Muller, Schornagel, Wever, and Aaronson (2000) found that patients
were willing to discuss QoL with their health care provider. In a sample of patients in
oncology practice, it was found that patients were very willing to discuss their physical
and emotional function; but while the patient felt comfortable initiating the discussion of
physical function, they expected that the provider would initiate any discussion of
emotional function including social and family issues. Providers on the other hand, in this
case physicians, tended to discuss emotional issues if the topic was initiated by the
patient. The authors concluded that this discrepancy as to who should take the lead in
discussion of psychosocial issues may decrease the likelihood that the discussion will
take place. Systematic clinical assessment of QoL would provide a catalyst for initiation
of conversation about social or emotional factors and QoL issues.
In order for QoL measures to become a part of clinical evaluation, barriers to the
use of QoL instruments must be addressed. In a study that examined the attitudes toward
the use of health outcome questionnaires in clinical practice Meadows, Rogers, and
Greene (1998) found that physicians in general practice and nurses expressed a positive
attitude about using health outcome measurements but were not sure how they would use
the data in patient care. Other identified barriers to the use of QoL outcome measures
include time and resource constraints, the perception that available instruments were
inadequate to measure outcomes, and the belief that QoL outcome measurements were
unnecessary (Morris, Perez, & McNoe, 1998). Familiarity with QoL questionnaires and
their use was associated with a more positive attitude toward incorporating them into
clinical practice in a sample of providers in a pediatric clinical practice (Baars, van der
Pal, Koopman, & Wit, 2004). A review of trials that assessed the influence of QoL
outcome measures on clinical decision-making noted that education regarding the
administration and interpretation of QoL measurement tools, presentation of results in a
usable format, and implementation in a manner reflecting the process of clinical decisionmaking would be helpful in overcoming barriers to using QoL measures in the clinical
setting (Greenhalgh et al., 2005). Benchmarks for QoL post transplantation based on
aggregate data, and presented in an easily interpretable format could provide tools that
would make the use of QoL outcome measures a beneficial part of patient assessment.
These tools would be used to evaluate the patient’s current QoL, alert the patient and
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provider to changes in QoL that have occurred, and identify points in the patient’s
recovery trajectory where strategies or interventions for improving QoL could be
implemented.
Centile Ranges to Interpret Quality of Life
If QoL outcome measurement is to be useful in the clinical setting, then tools that
aid in interpreting the values will be helpful for patients and providers. The establishment
of a range of QoL outcome measurement scores that are typical for patients at particular
points in time post transplantation would present the data in such a way that it has greater
utility in the clinical setting. Reference ranges, often referred to as normal ranges for
measurements, have long been used in health care to evaluate the health status of patients.
The range of normal for a particular variable is typically defined as the area between the
2.5th and the 97.5th percentiles (Griffiths, Iles, Koduah, & Nix, 2004). The assumption is
made that the reference population in which the variable is measured is a population
representative of “normal” or “healthy” individuals, thus the term normal range. The
simple reference range is inadequate for evaluation when the variable in question is
strongly dependent on a covariate such as time (Cole & Green, 1992). The tools
established to document human growth and the references used to monitor bone density
are common examples of reference ranges that have been established to follow change in
a variable over time. Development of time-related centile ranges for QoL outcomes based
on data collected from kidney transplant recipients that would the QoL experienced by
that population of patients would provide an adjunct to the evaluation of the patient’s
physical and disease specific outcomes in the clinical setting.
Summary
Improved graft survival and long-term patient survival following kidney
transplantation has led to a growing interest in addressing the QoL of patients (De Geest
& Moons, 2000). The wealth of data that is presently available regarding QoL and the
instruments that have been developed to measure QoL have not been translated into the
clinical setting for routine evaluation of QoL. Establishing benchmarks for the
assessment of QoL is an initial step in translating years of research into practice.
Standardized benchmark data would provide a baseline for interpreting individual patient
QoL outcomes in such a way that the information could be used to educate patients prior
to transplantation, allow transplant recipients to compare their QoL with others at similar
points in time post transplantation, and identify patients who could benefit from
interventions designed to improve QoL.
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CHAPTER 3. METHODOLOGY
Introduction
This chapter will describe the methodology used to address the research question
and study aim outlined in chapter one. It will include a discussion of the research design,
the sample and sampling method, and analytical plan.
Research Design
This descriptive study is a secondary data analysis focused on the development of
time-related centile ranges that document QoL outcome measure scores in four different
time blocks following kidney transplantation. Time-related centile ranges such as these
are used in clinical settings as benchmarks for patients and health care providers to
compare the patient’s status or progress with others having similar characteristics.
Research Question and Study Aim
The primary outcome of this study was the creation of time-related centile
reference ranges depicting QoL outcomes following kidney transplantation for use in
patient evaluation and education. The research question (1) and study aim (2) were as
follows:
1. Do QoL outcomes differ within groups of patients categorized by gender and
race? If so then:
a) Do the QoL outcome measures for patients grouped by gender and
race differ at four specific time intervals following transplantation?
b) Which of the variables or combination of variables (gender and race)
identify cohorts of patients most appropriate for creation of timerelated centile ranges used to illustrate QoL outcomes?
2. Individual time-related centile ranges were established for scores on the SF-12
and the Memphis Survey for each patient group identified in stage 1. The QoL
measures included separate scores for the:
a) SF-12:
i. Physical Component Summary (PCS)
ii. Mental Component Summary (MCS)
b) Memphis Survey scores:
i. Frequency score how often side effects occur)
ii. Severity score (level of distress caused by the side effects)
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Procedures
The Patient Outcomes Registry for Transplant Effects of Life (PORTEL) Survey,
a national data registry, was established in 2000 by Fujisawa Pharmaceuticals, and later
supported by Astellas Pharmaceuticals, in response to increasing concern regarding the
QoL of transplant recipients. The registry was designed to collect longitudinal data on
QoL outcomes following solid organ transplantation. The PORTEL database houses data
collected using a systematic approach to assessment of the QoL experienced by solid
organ transplant recipients. The intent in the development of the registry was to provide a
resource for data that could serve as a benchmark for evaluating the QoL of solid organ
transplant recipients in order to develop strategies to improve QoL (Hathaway et al.,
2003b). With this goal in mind, the PORTEL survey design was based on a
multidimensional QoL framework that encompassed both objective and subjective
indicators of QoL. The PORTEL registry is unique in that it is a stand alone patientdriven and patient-centered registry with data collected for the sole purpose of assessing
QoL. It was not a part of a larger clinical study with additional goals that could influence
the individual’s perception of their QoL.
The participants in the registry represent transplant recipients recruited from
multiple institutions and through multiple venues across the United States. Recruitment to
the registry was both patient-centric and site-centric. The patient-centric recruitment was
achieved through contact with transplant recipients at national transplantation meetings,
community events, support groups, and direct mail. Site-centric recruitment occurred
through four transplantation centers representing different regions of the United States,
Unversity of Southern California, University of Alabama, Birmingham, University of
Tennessee Health Science Center, and Unversity of Minnesota. Transplantation centers
participating in data collection received IRB approval from their institution prior to
enrollment of subjects (Hathaway, et al., 2003b). The PORTEL database represents a
more diverse sample of the population of transplant recipients than samples reported in
which data are collected from a single institution.
Participants were entered into the registry and data were collected from 20002005. PORTEL registry participants completed surveys at 6 month intervals during the
data collection period. Enrollment and participation in the registry was open to any solid
organ transplant recipient who had a functioning graft and was greater than 16 years of
age at the time that the survey was completed. All participants enrolled in the registry
were solid organ transplant recipients including, heart, lung, kidney, kidney-pancreas,
and liver transplant recipients. Participants received an incentive in the form of a $10
dollar Target gift certificate each time a survey was completed. Year to year retention in
the database was approximately 70 percent.
The design of the PORTEL Registry survey instrument was based on the four
cornered QoL framework discussed in chapter one. The instrument was comprised of 100
items organized to capture demographic variables, clinical outcomes, medications, and
side effects (Hathaway, Winsett, Prendergast, & Subaiya, 2003). The content of the
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survey addressed each of the five domains described in the QoL framework for the
registry: QoL, health factors, social factors, major health factors, and major life events.
Quality of Life Instruments Included in the PORTEL Registry Survey
12-Item Short-Form Health Survey
The SF-12 is an instrument that has been used to document QoL in the general
population as well as groups of patients with various chronic illnesses. It is comprised of
a subset of 12 items from the SF-36 and was developed to provide an alternative to the
longer form, be easier to administer and yet provide the same reliability as the longer SF36 (Ware, Kosinski, & Keller, 1996). The SF-36 has been widely used to evaluate health
related quality of life in transplant recipients and is considered the gold standard for
measuring QoL (Aasebo, Midtvedt, Hartmann, & Stavem, 2005; Fiebiger, Mitterbauer, &
Oberbauer, 2004; Griva et al., 2002; Pinson et al., 2000; Rebollo et al., 2000). The SF-12
has been shown to correlate with the SF-36 in assessing QoL trauma patients, individuals
with cervical spondylosis, and persons infected with HIV (Delate & Coons, 2000; Kiely,
Brasel, Guse, & Weigelt, 2006; Singh, Gnanalingham, Casey, & Crockard, 2006).
The SF-12 is composed of two domains comprising a Mental (MCS) and Physical
Component Summary (PCS). Mental and physical factors were found to account for 80 to
85 percent of the variance in the SF-36 (Ware et al., 1996). Psychometric methods were
used to reduce the number of health dimensions in the SF-36 to those included in the SF12 and maintain comparable information (Ware et al., 1996). The SF-12 is scored from 0100 with higher scores indicating better QoL.
Memphis Survey
A disease specific instrument, the Memphis Survey was included in the PORTEL
instrument to document side effects of immunosuppressant medications. The survey was
developed in 1997 by a group of researchers at University of Tennessee Health Science
Center. The development of the Memphis Survey was unrelated to the establishment of
the PORTEL registry (Hathaway et al., 2003b). The survey was designed to evaluate the
frequency and severity of side-effects of immunosuppressive regimens on QoL in solid
organ transplant recipients (Hathaway et al., 2003b). A multi-stage factor analysis was
used to identify side effects experienced by patients taking a variety of
immunosuppressant agents (Winsett et al., 2004). The subscales of the Memphis survey
are emotional burden, life/role responsibilities, mobility, gastrointestinal distress, and
miscellaneous side-effects which include items related to enlarged gums, increased
hunger, sleeping, weight gain, increased hair growth, infections, trembling hands, high
blood pressure, easy bruising, loss of interest in sex, and sexual performance (Winsett et
al., 2004). Symptoms were assessed for occurrence and the level of distress incurred by
the patient. Symptoms were coded on a 0-4 scale, zero being not at all and 4 being
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always. Cumulative subscale scores for frequency of occurrence and severity of the
symptom were reported for each patient ranging from 0-160. The higher number
indicating a worse side-effect profile (Hathaway et al., 2003b). Reliability and validity of
the Memphis Survey was demonstrated by Winsett, et al. (2004) in a national survey of
505 transplant recipients designed to quantify the consequences of the side effects of
immunosuppressant therapy on QoL.
Data Extraction
Data for this study were extracted from the PORTEL Registry database. Inclusion
criteria for the study were recipients of a single kidney transplantation who were between
the ages of 18 and 65 at the time the survey was completed and greater than 14 days from
the transplant surgery. The total PORTEL database includes 7,327 surveys completed by
1,434 recipients of solid organ transplantation. The initial data extraction identified 3,144
surveys completed by 681 individuals who had undergone single kidney transplantation.
Time intervals were established for construction of time-related centile ranges
representing four separate time brackets between the transplant surgery and survey
completion: less than 4 months from transplantation, 4 months to 18 months, 19 months
to 36 months, and greater that 36 months from transplantation. These specific time
brackets were selected to allow for even distribution of the surveys and to be consistent
with times typically used for clinical assessment of patients and in post-transplantation
follow-up studies. Because individuals contributed multiple surveys to the database, care
was taken to assure that only one survey from each individual transplant recipient was
included in each time bracket. The first survey completed by an individual within each
time bracket was selected for inclusion. If a patient contributed additional surveys, the
others were excluded. This process eliminated 1,894 surveys leaving 969 for study
inclusion in the study.
Only Caucasian and African American participants were selected for inclusion in
the study because the number of participants of other ethnic or racial association was
inadequate for data analysis. Of the 969 surveys selected, 22 surveys were eliminated
because they did not include QoL data and 4 surveys were eliminated because they did
not include information about gender. The final sample consisted of 943 surveys
completed by 515 recipients of a single kidney transplantation.
Demographic data, clinical information and QoL outcomes were extracted from
each survey to describe the sample and address the research question and study aim.
Demographic data included age, income, education, working status, social support, living
arrangements, immunosuppressant regimens, and insurance coverage. Clinical
information included comorbidities, number of infection and rejection episodes,
frequency of hospitalization and number of hospital days since transplantation. Data
extracted to address the research questions included race, gender, the Memphis Survey
Frequency and Severity scores and the SF-12 PCS and MCS scores.
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Sample
The 943 PORTEL Registry Surveys included in this study were completed by 515
individuals, 246 contributed a survey in only one time bracket, 128 individuals
contributed a survey in each of two time brackets, 123 contributed a survey in three time
brackets, and 18 transplant recipients contributed a survey in all 4 time brackets. No
PORTEL Registry participant was represented in any time bracket more than once. The
description of the sample is reported by time intervals since transplantation in order to
provide a description of the portion of the sample included in each time bracket.
Description of the Sample
The 943 surveys were completed by 484 (51.3%) men and 459 (48.7%) women.
Seven hundred fifty one (79.6%) were completed by Caucasians and 192 (20.4%) by
African Americans. The average age at the time of survey completion was 46 years with
a standard deviation of 11.3 years.
The gender and race distribution of the individual transplant recipients included in
this study was compared to the data from the United Network for Organ Sharing (UNOS)
data. UNOS administers the Organ Procurement and Transplantation Network (OPTN)
and is responsible for collecting and managing data about all transplantation events that
occur in the United States. The distribution of racial and gender groups in the PORTEL
sample differs from that of the UNOS data (χ2 = 25.03, α=0.01). A comparison of the
gender and racial distribution of this sample with the UNOS data is presented in Table
3.1. The percentage of Caucasian males and African-American females in the sample
from the PORTEL registry were consistent with the population reported by UNOS.
However, African American males comprised only 9.5% of the study sample compared
with 16.24% reported by UNOS. The percentage of Caucasian females in the study
sample was higher than that reported in the UNOS database, 35.7% and 28.52%
respectively.
Health Status
Health status includes both the health factors and major health events that
transplant recipients deal with on a daily basis and episodically which impact QoL
(Hathaway et al., 2003b). Comorbidities, rejection episodes, hospital admissions, hospital
days and infections that were reported on each survey were included in the study. The
PORTEL Survey is a self-report questionnaire; as a result all surveys were not complete.
Comorbidities. Increased long term survival of transplant recipients leads to
increased prevalence of secondary complications of transplantation, including
osteoporosis (Cohen & Shane, 2003; Crippin, 2001), diabetes, and hyperlipidemia

22

Table 3.1. Comparison of Sample Demographic Distribution with UNOS Data.
Demographic Group

PORTEL Sample

UNOS

Caucasian Male

42.3%

44.16%

Caucasian Female

35.7%

28.52%

African American Male

9.5%

16.24%

African American Female

12.4%

11.10%

*Based on OPTN data as of May 8, 2008.
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(Reuben, 2001). Comorbidities, either pre-existing or those that develop following
transplantation have an impact on the well-being and QoL of transplant recipients. The
survey asked participants if they had been treated for diabetes, hypertension,
hypercholesterolemia, or osteoporosis since transplantation. Treatment for comorbidities
was reported on 761 surveys.Interestingly, 200 surveys reported no comorbidities.
Multiple comorbidities were reported on 328 surveys, 200 reported two, 106
reportedthree and 22 reported treatment for four comorbidities. Table 3.2 reports the
percent of surveys reporting treatment for hypertension, cholesterol, diabetes, or
osteoporosis ineach time bracket. The incidence of diabetes and hypertension are
relatively stable across time.
The frequency of treatment for osteoporosis and hypercholesterolemia is lower for
individuals in the early months post transplantation and was increased at the points
farthest removed from the transplantation. At less than 4 months post transplantation,
4.7% of surveys reported treatment for osteoporosis and 25.7% reported treatment for
hypercholesterolemia. At greater than 36 months post transplantation, 23% of surveys
reported treatment for osteoporosis and 46.7% reported treatment for
hypercholesterolemia.
Rejection, Infection, Hospital Admissions, and Hospital Days. The incidence of
rejection episodes in the sample is low with the majority of surveys reporting no rejection
episodes. The peak period for rejection was in the 4-18 month post transplant block with
10.3% of surveys reporting 1 to 2 rejection episodes representing 26 surveys. Table 3.3
lists the incidence of rejection episodes in each time bracket.
Frequency of infection was reported as the number of infections treated since
transplantation. No information was available regarding severity of infection. Most
surveys reported that no treatment for infection had been required since transplantation.
Of those reporting that they had been treated for an infection, the most common number
of infections reported was 1 to 2. Over time, the number of infections was relatively
stable. The actual number of infections reported in each time bracket is reported in Table
3.4.
The number of hospital admissions and the number of days spent in the hospital is
reported in Tables 3.5 and 3.6. The reported frequency of hospital admissions or hospital
days in each time bracket represents the cumulative number of hospitalizations or
hospital days since transplantation, not the number occurring during the designated time
bracket. The majority of surveys reported no hospitalizations since transplantation. A
greater percentage of surveys reported no hospital days at greater than 36 months post
transplantation (53.3%) than at less than 4 months post transplantation (29.2%). Few
surveys reported 5 or more hospitalizations in any time bracket and few surveys reported
more than 21 days in hospital. More hospital days were reported during the less than 4
month post transplantation period than the later time blocks, which would be consistent
with surgical recovery. The percentage of survey that did not report health status
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Table 3.2. Comorbidity by Time Bracket Since Transplantation.
Time Since Transplantation
Cormorbidity
Diabetes
Hypertension

<4 months
n=213

4-18 months
n=213

19-36 months
n=199

>36 months
n=134

50
23.4%

43
20.2%

47
23.6%

37
27.4%

106
49.8%

113
56.8%

80
59.3%

118
55.1%

Osteoporosis

10
4.7%

30
14.1%

48
24.1%

31
23.0%

Increased
Cholesterol

55
25.7%

76
35.7%

94
47.2%

63
46.7%
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Table 3.3. Frequency of Rejection Episodes by Time Since Transplantation.
Time Since Transplantation
<4 months
n=236

4-18 months
n=253

19-36 months
n=225

>36 months
n=229

0

200
84.7%

208
82.2%

203
90.2%

181
79%

1-2

15
6.4%

26
10.3%

12
5.3%

7
3.1%

3-4

5
2.1%

2
.8%

1
.5%

3
1.3%

5 or more

4
1.7%

0
.0%

0
.0%

1
.4%

Unknown

12
5.1%

17
6.7%

9
4%

Rejection
Episodes

26

37
16.2%

Table 3.4. Number of Reported Infections by Time Since Transplantation.
Time Since Transplantation
<4 months
n=236

4-18 months
n=253

19-36 months
n=225

>36 months
n=229

0

152
64.4%

153
60.5%

152
67.6%

138
60.3%

1-2

61
25.8%

67
26.5%

55
24.4%

42
18.3%

3-4

4
1.7%

13
5.1%

8
3.6%

13
5.7%

5 or more

1
0.4%

0
.0%

2
0.9%

3
1.3%

Unknown

18
7.9%

20
7.9%

8
3.6%

33
14.4%

Infections
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Table 3.5. Frequency of Hospital Admissions by Time Since Transplantation.
Time Since Transplantation
<4 months
n=236

4-18 months
n=253

19-36 months
n=225

>36 months
n=229

0

162
68.6%

163
64.4%

180
80%

153
66.8%

1-2

57
24.2%

61
24.1%

31
13.8%

20
8.7%

3-4

5
2.1%

7
2.8%

2
.9%

7
3.1%

5 or more

1
0.4%

3
1.3%

1
0.4%

1
0.4%

Unknown

11
4.7%

19
7.5%

11
4.9%

48
21%

Hospital
Admissions
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Table 3.6. Number of Hospital Days by Time Since Transplantation.
Time Since Transplantation
<4 months
n=236

4-18 months
n=253

19-36 months
n=225

>36 months
n=229

0

69
29.2%

127
50.2%

134
59.6%

122
53.3%

1-10

116
49.2%

84
33.2%

70
31.1%

52
22.7%

11-20

22
9.3%

12
4.7%

5
2.2%

4
1.7%

21-30

11
4.7%

6
2.4%

3
1.3%

1
0.4%

>31

7
3.0%

4
1.6%

1
0.4%

2
0.9%

Unknown

11
4.7%

20
7.9%

12
5.3%

48
21%

Hospital Days
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indicators was higher in the greater than 36 months post transplantation group than in any
other group (21%).
Immunosuppressant Regimen. The current immunosuppressant regimen was
reported on 760 surveys. The drugs included in the immunosuppressant regimens
indicated on the surveys are reported in Table 3.7. Prednisone, the calcineurin inhibitors,
cyclosporine and tacrolimus, and mycophenolate mofetil (Cellcept), an antiproliferative
agent, were the most common agents indicated. The majority of surveys (62%) reported a
3 drug regimen.
Social Factors
Social factors, including the individual’s marital status, social support, and
working status have been reported to correlate with better QoL in a number of studies
(Blake, Codd, Cassidy, & O'Meara, 2000; Yildirim, 2006). The QoL framework that
forms the basis for both the PORTEL registry and this study included social support,
health care coverage and financial resources.
Social Support. Social support data collected through the PORTEL survey
included the individual’s living situation and the assistance that was available to them.
Most surveys reported that the transplant recipient lived with their spouse or a significant
other, with percentages ranging from 64.4% to 71.1%. More people reported living alone
at greater than 36 months following transplantation (18.3%) than in the earlier time
brackets (Table 3.8).
Social support in the form of available assistance ranged from “no available
assistance” to “more people available to help than I can count”. Very few surveys
reported that the individual had no available assistance. Most survey reported that they
had people available to assist them when needed (Table 3.9). Assistance was not defined.
Health Care Coverage. Health care coverage was reported by the majority of
participants. Medicare was most frequently reported with 621 surveys indicating
Medicare coverage. Medicaid enrollment was reported on only 92 surveys. Private
insurance was reported by 578 individuals. Both private and public health care coverage
was reported by 321 individuals. Table 3.10 reports health care coverage by time bracket
since transplantation.
Employment, Income, Education. Employment has been shown to correlate with
better QoL (Neipp et al., 2006). The working status of the individual was reported on
only 440 of the 943 surveys. Of that number, 203 (46.1%) across all time brackets
reported that they were working full-time or part time. Examination of all time brackets
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Table 3.7. Immunosuppressant Agent by Time Since Transplantation.
Time Since Transplantation
<4 months
n=214

4-18 months
n=213

19-36 months
n=199

>36 months
n=136

155
72.4%

151
70.9%

139
69.8%

115
85.2%

2
.9%

4
1.9%

4
2.0%

14
10.4%

Prograf

110
51.4%

109
51.2%

101
50.8%

59
43.7%

Neoral

71
33.2%

79
37.1%

55
27.6%

45
33.6%

Generic
Cyclosporine

6
2.8%

11
5.2%

20
10.1%

17
12.7%

Mycophenolate
Mofetil (Cellcept)

159
74.3%

162
76.1%

135
67.8%

83
61.9%

Rapamune

28
13.1%

34
16.0%

35
17.6%

12
9.0%

Other

16
7.5%

13
6.1%

13
6.5%

8
6.0%

Immunosuppressant
Agent
Prednisone
Imuran
Calcineurin
Inhibitors:
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Table 3.8. Living Situation by Time Bracket Since Transplantation.
Time Since Transplantation
<4 months
n=236

4-18 months
n=253

19-36 months
n=225

>36 months
n=229

Living with spouse
or significant other

152
64.4%

175
69.2%

160
71.1%

149
65.1%

Single, living with
family or friends

51
21.6%

39
15.4%

31
13.8%

31
13.5%

Single, living alone

26
11%

31
12.3%

27
12%

42
18.3%

Widowed

4
1.7%

4
1.6%

5
2.2%

3
1.3%

3
1.3%

4
1.6%

2
.9%

4
1.8%

Living Situation

Unknown
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Table 3.9. Available Assistance by Time Since Transplantation.
Time Since Transplantation
Available
Assistance
More people
available than I
can count
Several friends and
family available
Just a few friends
and family
No available to
help
Unknown

<4 months
n=236

4-18 months
n=253

19-36 months
n=225

>36 months
n=229

32
13.6%

44
17.4%

49
21.8%

27
11.9%

116
49.2%

92
36.4%

59
26.2%

85
37.4%

78
33.1%

105
41.5%

100
44.4%

95
41.5%

5
2.1%

6
2.4%

8
3.6%

15
6.6%

5
2.1%

6
2.4%

9
4.0%

7
3.1%
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Table 3.10. Health Care Coverage by Time Since Transplantation.
Time Since Transplantation
<4 months
n=236

4-18 months
n=253

19-36 months
n=225

>36 months
n=229

Medicare

170
72%

185
73.1%

165
73.3%

101
44.1%

Medicaid

50
21.2%

15
6%

15
7%

12
5%

Private Insurance

134
56.8%

147
58.1%

148
65.8%

149
65.1%

Health Care
Coverage
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revealed that 153 (34.7%) surveys reported that the respondent was not working; 139
(31.6%) due to their disease and 14 (3%) by choice. The number employed in each time
brackets is reported in Table 3.11.
The annual income and education level of the participants in the sample is
reported in Tables 3.12 and 3.13. Reported income ranged from less than $10,000 to
greater than $151,000. The source of income was not indicated. Education ranged from
less than eighth grade to post graduate or professional school. The most frequent response
in all time brackets was some college or technical school.
Analytical Plan
The study progressed in two phases guided by the research question and study
aim. Phase 1 addressed the research question and identified how the study sample
differed on QoL outcomes based on gender and race, at four separate time brackets posttransplantation. Phase 2 of the study focused on the study aim which involved generating
time-related centile ranges to be used in clinical practice to monitor and evaluate kidney
transplant recipients.
Research Question
The QoL outcome measures for each racial and gender specific demographic
group were compared at each time following transplantation in order to determine if the
scores on each QoL outcome by racial and gender specific demographic group were
homogenous enough to include all groups in a single centile range. Descriptive statistics
for the QoL outcomes SF-12, MCS and PCS scores, and Memphis Survey Frequency and
Severity scores of each group were completed including the mean, median, range,
standard deviation and tests for normality at each time point post transplantation. The
QoL outcome scores for each group at each time bracket were not normally distributed.
In addition, the number of scores in the African American population was fewer than that
required for the Central Limit Theorem to apply (n=30) for the use of parametric
statistics. Therefore, a nonparametric statistical procedure, the Kruskal-Wallis test was
used to evaluate differences between gender and racial groups for the QoL outcome
scores at each time bracket post transplantation.
Study Aim: Construction of Centile Ranges
Time-related centile ranges were constructed by using SPSS 15 to identify the
5th, 25th, 50th, 75th, and 95th percentiles for each QoL outcome at each time point.
These percentiles were plotted for each QoL outcome at each time bracket following
transplantation.
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Table 3.11. Employment Status by Time Since Transplantation.
Time Since Transplantation
<4 months
n=142*

4-18 months
n=125

19-36 months
n=94

>36 months
n=79

Working full time

30
21.1%

47
37.6%

47
50%

38
48.1%

Working part time
by choice

5
3.5%

10
8%

3
3.2%

3
3.8%

Working part time
due to disease

8
5.6%

7
5.6%

1
1.1%

4
5.1%

Not working by
choice

3
2.1%

3
2.4%

4
4.3%

4
5.1%

Not working due
to disease

68
47.9%

31
24.8%

21
22.3%

19
24.1%

Not working,
unable to find
employment

5
3.5%

7
5.6%

5
5.3%

5
6.3%

Retired

23
16.2%

20
16%

13
13.8%

6
7.6%

Employment
Status

* n = number reporting employment status
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Table 3.12. Annual Income by Time Since Transplantation.
Time Since Transplantation
<4 months
n=236

4-18 months
n=253

19-36 months
n=225

> 36 months
n=229

<$10,000

37
16.7%

27
11.5%

21
10.4%

23
10.6%

$11,000-$25,000

37
16.7%

47
20.1%

34
16.8%

30
13.8%

$26,000-$50,000

49
22.1%

67
28.6%

61
30.2%

64
29.8%

$51,000-$75,000

34
15.3%

35
15.0%

39
19.3%

41
19.1%

$76,000-$150,000

29
13.1%

25
10.7%

17
8.4%

19
8.8%

>$151,000

5
2.3%

10
4.3%

9
4.5%

10
4.7%

Unknown

45
19.2%

42
16.6%

44
19.6%

42
18.3%

Annual Income
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Table 3.13. Education by Time Since Transplantation.
Time Since Transplantation
<4 months
n=236

4 - 18 months
n=253

19 - 36 months
n=225

> 36 months
n=229

8th grade or less

5
2.1%

2
.8%

1
.4%

4
1.8%

9th-12th grade

17
7.2%

9
3.6%

8
3.6%

6
2.6%

High School

57
24.2%

63
24.9%

49
21.8%

40
17.5%

Some college or
technical school

90
38.1%

101
39.9%

91
40.4%

92
40.5%

4-year
Baccalaureate
College

43
18.2%

51
20.2%

45
20.0%

52
22.9%

Graduate School

11
4.7%

14
5.5%

18
8.0%

20
8.8%

Postgraduate/
Professional
School

9
3.8%

11
4.3%

10
4.4%

14
6.2%

Unknown

4
1.7%

2
.8%

3
1.3%

1
.4%

Education
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CHAPTER 4. RESULTS
The results and discussion section of this dissertation have been written in
manuscript format. As a result supporting material, including descriptive statistics for
the Memphis Survey Subscale Scores, the Memphis Survey Total Scores, and the SF-12
scores which are of interest for the purposes of the dissertation but not necessarily for a
manuscript have been placed in Appendices A and B. Background material presented in
other chapters has been included in this section to provide the information necessary for
a manuscript.
Introduction
Quality of life (QoL) is commonly viewed as an important indicator of successful
chronic illness management (Leplege & Hunt, 1997), particularly for conditions such as
renal failure in which transplantation is the preferred therapy primarily because of the
associated improvement in QoL (Feibiger, Mitterbauer, & Oberbauer, 2004). Despite
extensive research, routine assessment of QoL has not been widely translated into clinical
practice as a means to augment clinical decision making, identify patients who would
benefit from interventions, or to educate patients about anticipated QoL outcomes
(Higginson & Carr, 2001). Kidney transplantation is no exception.
Time-related centile ranges have been developed for many clinical outcomes such
as growth and bone density, and provide reference ranges that are used to interpret a
patient’s health status as compared to a normative population, or to monitor disease.
Similar reference ranges for QoL outcome data would provide a context for interpreting
QoL data for patients and providers in the transplantation setting. The purpose of this
study was therefore to create time-related centile ranges from data collected in a national
data registry that depict QoL outcomes in such a way that they that could be used as
benchmarks in evaluating the QoL of patients following kidney transplantation in the
clinical setting.
Background and Significance
QoL has been described as the difference between the patient’s expectation of a
situation and their actual experience (Carr, Gibson, & Robinson, 2001). The patient’s
assessment of their QoL following kidney transplantation may be shaped by their pretransplantation expectations of what life after transplantation would be like. Patients
contemplating transplantation or being followed post transplantation often seek
information related to QoL expectations following transplantation and how their QoL
compares with other transplant recipients. Benchmarks that reflect QoL following kidney
transplantation would provide an additional tool in the clinical armamentarium to
augment post transplantation care by providing a context for interpreting QoL measures.
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There are relatively few examples in which QoL measurement has been used to
guide clinical decision making for individual patients (Levine & Ganz, 2002). While
there is general agreement that discussion of QoL is beneficial, few studies have
demonstrated that measuring QoL outcomes actually changes clinical decision making or
patient outcomes (Espallargues, Valderas, & Alonso, 2000; Greenhalgh, Long, & Flynn,
2005). However, even in studies that do not demonstrate changes in clinical or QoL
outcomes, measuring QoL in routine practice has been demonstrated to increase
communication between patients and providers about QoL indicators (Detmar, Muller,
Schornagel, Wever, & Aaronson, 2002). Measuring QoL in oncology practice, and
providing feedback to patients, has led to increased discussion of nonspecific symptoms
and better QoL and emotional functioning without prolonging the duration of patient
encounters (Velikova et al., 2004). Although most studies using QoL instruments did not
demonstrate changes in clinical decision making or QoL outcomes, the process of
increasing communication seems to have benefit in patient care. Higginson & Carr
(2001) cite several potential uses for QoL measures in the clinical setting directly related
to clinical care including prioritizing problems, facilitating communication, screening for
potential problems, identifying preferences of patients and monitoring changes or
responses to treatments. While QoL measures do not substitute for physiologic evaluation
of disease, they capture the personal and social context of the patient for a more holistic
approach to patient assessment.
Time-Related Centile Ranges
Reference ranges, often referred to as normal ranges, have long been used in health
care to evaluate the health status of individual patients on some specific parameter by
comparing them to an standard established from a “normal” population (Wright &
Royston, 1997). The range of normal for a given variable is typically defined as the range
of values for that variable that fall between the 2.5th and the 97.5th percentile in the
population of interest (Griffiths, Iles, Koduah, & Nix, 2004). The assumption is made
that the reference population in which the variable is measured is a healthy population
representative of “normal” or “healthy” individuals, thus the term normal range. The
variables that are reported in a reference range are often affected by other characteristics
of the representative population (Wright & Royston, 1997). When the variable in
question is strongly dependent on a covariate such as time, a simple reference range is
inadequate for evaluation (Cole & Green, 1992). A common example of a reference
range established to follow change in a variable over time is the series of ranges that have
been established to monitor growth rates in childhood. Growth charts are routinely used
by health care providers to evaluate the growth of children over time, to identify those
children who are not growing at the anticipated rate, or whose height or weight is outside
of the desired range. The time-related centile ranges for QoL outcomes of kidney
transplant recipients proposed in this study could be used in a similar manner to follow
QoL outcomes over time as well as a evaluating QoL at a particular point in time.
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Methods
PORTEL Registry
Data for the creation of time-related centile ranges in this study was extracted
from the Patient Outcomes Registry for Transplant Effects on Life (PORTEL), a national
data registry, established in 2000 by Fujisawa Pharmaceuticals, and later supported by
Astellas Pharmaceuticals, in response to increasing concern regarding the QoL of
transplant recipients. The registry was designed to collect longitudinal data on QoL
outcomes following solid organ transplantation and incorporated a systematic approach to
the assessment of QoL experienced by solid organ transplant recipients. The intent of the
registry was to provide a resource for QoL data that could serve as a benchmark for
assessing QoL in solid organ transplantation leading to the development of strategies to
improve QoL (Hathaway et al., 2003b). With this goal, the PORTEL survey design was
based on a multidimensional QoL framework that included five interrelated domains;
health and social factors, major life and health events and QoL. Health factors are those
issues that individuals deal with on a daily basis that influence QoL such as the effects of
immunosuppressant drugs and co-morbidities that require daily attention and therefore
influence QoL. Social factors include situations and events that define an individual’s
social environment and include the financial resources available to the individual, health
care coverage, and the social support that the transplant recipient has (Hathaway et al.,
2003b). Major life and health events are more episodic in nature but may be more
disruptive to the established routine of the individual or the family (Hathaway et al,
2003b). Major health events include rejection episodes, hospitalizations, or a new
diagnosis. A major life event as defined in the PORTEL framework may be a divorce,
death in the family, or loss of a job. Health and social factors and major life and health
events influence, and are influenced by, the QoL that an individual is experiencing. The
PORTEL survey instrument was a 100 item survey developed to assess the five domains
included in the PORTEL framework.
The PORTEL registry was a stand alone patient-driven and patient-centered
registry with data collected for the sole purpose of assessing QoL. The participants in the
registry represent transplant recipients recruited from multiple institutions and through
multiple venues across the United States. Recruitment to the registry was both patientcentric and site-centric. Patient-centric recruitment was achieved through contact with
transplant recipients at national transplantation meetings, community events, support
groups, and direct mail. Site-centric recruitment was accomplished through four
transplantation centers representing different regions of the United States; Unversity of
Southern California, University of Alabama, Birmingham, University of Tennessee
Health Science Center, and University of Minnesota. Transplantation centers
participating in data collection received IRB approval from their institution prior to
enrollment of subjects (Hathaway, Winsett, Prendergast, & Subaiya, 2003). The
PORTEL database represented a more diverse sample of the population of transplant
recipients than a sample drawn from a single institution and, as such, was appropriate for
creation of time-related centile ranges for use in a variety of settings.
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It has been recommended that evaluation of QoL should include a generic QoL
instrument and a disease specific instrument (Hathaway, Winsett, et al., 2003). The 12Item Short Form-Health Survey (SF-12) was chosen by the designers of the PORTEL
survey as the generic instrument and the Memphis Survey as the disease specific
instrument. The SF-12 has been used to document QoL in the general population as well
as in the evaluation of QoL of patients with a variety of chronic conditions. Comprised of
a subset of 12 items derived from the 36-Item Short-Form Health Survey (SF-36), the
gold standard for assessment of QoL, the SF-12 was developed to provide an alternative
instrument that would be shorter, easier to administer and yet provide the same reliability
as the longer SF-36 (Ware, Kosinski, & Keller, 1996). The SF-12 has been correlated
with the SF-36 in assessing QoL of trauma patients, individuals with cervical
spondylosis, and persons infected with HIV (Delate & Coons, 2000; Kiely, Brasel, Guse,
& Weigelt, 2006; Singh, Gnanalingham, Casey, & Crockard, 2006). The SF-12 is
composed of two domains, the Mental Component Summary and Physical Component
Summary. Each Summary is scored on a 0-100 scale with higher scores indicating better
QoL.
The Memphis Survey was included in the PORTEL survey to document side
effects of immunosuppressant medications. The survey was developed in 1997 by a
group of researchers at University of Tennessee Health Science Center. The instrument
was designed to evaluate the frequency and severity of side-effects of
immunosuppressant regimens on QoL in transplant recipients (Hathaway, Winsett, et al.,
2003). A multi-stage factor analysis was utilized to identify those side effects
experienced by patients on a variety of immunosuppressant regimens (Winsett et al.,
2004). The subscales included in the Memphis survey are emotional burden, life/role
responsibilities, mobility, gastrointestinal distress, and miscellaneous side-effects which
include items related to enlarged gums, increased hunger, sleeping, weight gain,
increased hair growth, infections, trembling hands, high blood pressure, easy bruising,
loss of interest in sex, and sexual performance (Hathaway, Winsett, et al., 2003).
Symptoms are assessed for frequency of occurrence and the severity of the side effect and
coded on a 0-4 scale. Total scores are tabulated from the subscale scores for frequency of
occurrence and for severity of the symptom to provide an overall estimate of the side
effect profile and degree of distress. Memphis Survey total scores range from 0-160, the
higher number indicating a worse side-effect profile (Hathaway, Winsett, et al., 2003).
Reliability and validity of the Memphis Survey has been demonstrated by Winsett, et al.
(2004) in a national survey of 505 kidney transplant recipients.
Data Extraction
Data for this study were extracted from the PORTEL Registry database. The total
PORTEL database includes 7,327 surveys completed by 1,434 recipients of any solid
organ transplantation. Inclusion criteria for the current study were Caucasian and African
American PORTEL registry participants between the ages of 18 and 65 who had
undergone one kidney transplantation and were greater than 14 days from transplant
surgery when the survey was completed. Initial data extraction identified 3,144 surveys
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completed by 681 individuals who had undergone a single kidney transplantation.
PORTEL data were collected longitudinally over a five year period, as a result, individual
transplant recipients contributed multiple surveys to the registry.
Four separate time brackets between the transplantation surgery and completion
of the survey were established for construction of time-related centile ranges: less than 4
months from transplantation, 4 months to 18 months, 19 months to 36 months, and
greater that 36 months from transplantation. The identified time brackets allowed for
even distribution of the surveys and were consistent with times typically used for clinical
follow-up and in post-transplantation studies. Only one survey from each individual was
included in each time block for which time-related centile ranges were established. The
first survey completed by an individual within each time bracket was selected for
inclusion leaving 943 surveys completed by 515 recipients; 246 individuals were
represented in only one time bracket, 128 individuals contributed a survey to two time
brackets, 123 contributed a survey to three time brackets, and 18 transplant recipients
contributed a survey to all 4 time brackets.
Sample
Of the 943 surveys included in the study, 484 (51.3%) were men and 459 were
(48.7%) women. Seven hundred fifty one (79.6%) surveys were completed by
Caucasians and 192 (20.4%) by African Americans. The average age at survey
completion was 46 years with a standard deviation of 11.3 years. The gender and racial
distribution of the sample in this study was compared to the data from the United
Network for Organ Sharing (UNOS) data and is reported in Table 3.1.
Data Analysis
The Qol outcome scores for each group at each time bracket were not normally
distributed. In addition, the number of scores in the African American population was
fewer than that required for the Central Limit Theorem to apply (n=30) for the use of
parametric statistics. Therefore, a nonparametric statistical procedure, the Kruskal-Wallis
test was used to evaluate the differences between gender and racial groups for the QoL
outcome scores at each time bracket post transplantation. A p-value of.05 was set for
statistical significance.
Differences in SF-12 Scores by Racial and Gender Groups
No differences were found between MCS mean ranks for the demographic groups
at any of the four time brackets (Table 4.1). Similarly, no differences were found
between the mean ranked PCS scores at less than 4 months, 4 months to18 months or
greater than 36 months. However, a significant difference between the mean ranked PCS
scores was seen at 19 months to 36 months post transplantation (p=.047), where the mean
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Table 4.1. Kruskal-Wallis Ranks and Test Statistics for Differences in MCS Scores
between Demographic Groups at <4 Months, 4-18 Months, 19-36 Months and >36
Months Post-Transplantation.
<4 months

4-18 months

19-36 months

>36 months

Racial/Gender
Group

N

Mean
Rank

N

Mean
Rank

N

Mean
Rank

N

Mean
Rank

Caucasian
Male

94

108.64

94

119.21

89

98.99

90

102.41

Caucasian
Female

66

106.32

86

113.19

82

108.67

83

99.64

21

112.19

16

90.78

14

109.71

12

124.29

30

92.68

30

108.60

22

103.23

18

96.00

African
American
Male
African
American
Female

χ2 =1.821
df=3
p=.610

χ2 =2.820
df=3
p=.420
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χ2 =1.253
df=3
p=.740

χ2 =2.054
df=3
p=.561

rank of African American women (92.68) was lower than that of Caucasian men
(108.64), Caucasian women (106.32), or African American men (112.19) (Table 4. 2).
Figures 4.1 and 4.2 illustrate the mean MCS and PCS scores by demographic group.
There were minimal differences in the actual mean scores between the groups across the
time brackets and although the Kruskal-Wallis Test found a statistical difference in PCS
scores, the actual scores are closely grouped.
Differences in Memphis Survey Scores by Racial and Gender Groups
Memphis Survey Frequency mean rank scores were only found to differ at less
than 4 months post transplantation (p=.021) with African American men reporting better
QoL (lower scores) as it relates to the frequency of immunosuppressant side effects
(Table 4.3). No differences were found between mean ranks of the Memphis Survey
Severity scores (Table 4.4). Bar graphs for the means of both Memphis Survey scores
also illustrate, that scores are very closely grouped (Figures 4.3 and 4.4).
Construction of Time-Related Centile Ranges
The Kruskal-Wallis analyses demonstrated a strong degree of homogeneity
among racial and gender specific demographic groups with only 2 of 16 QoL outcome
measures found to be significantly different. The two scores that differed were from
different instruments (PCS from the SF-12 and Memphis Survey Frequency) and were
from different time periods (19 months to 36 months for the PCS and less than 4 months
for the Memphis Survey Frequency). Moreover, the variation in the means across the
groups was small (PCS at 19 months to 36 months means ranged from 38.15 to 45.99 on
a 100 point scale; Memphis Frequency at less than 4 months means ranged from 32.98 to
49.63 on an 160 point scale) leading to the conclusion that negligible clinical differences
exist for the QoL outcomes for racial and gender subgroups regardless of the finding that
two of the scores differed statistically. Therefore, only one time-related centile range was
required to adequately represent the QoL outcomes for this cohort of kidney transplant
recipients.
The time-related centile ranges for PCS scores, MCS scores, Memphis Survey
Frequency Scores, and Memphis Survey Severity Scores are pictured in Figures 4.5 and
4.6. The design for the time-related centile range enables assessment of QoL of an
individual at four separate time brackets following transplantation. Subscales of the SF12 and Memphis Survey are depicted on the same page for ease of use and comparison.
Better QoL is indicated by higher scores on the SF-12 but by lower scores on the
Memphis Survey; therefore the y-axis of the Memphis Survey centile ranges has been
inverted for consistency in visualization of the scores. The darker shading on each bar
corresponds to improved QoL scores.
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Table 4.2. Kruskal-Wallis Ranks and Test Statistics for Differences in PCS Scores
between Demographic Groups at <4 Months, 4-18 Months, 19-36 Months and >36
Months Post-Transplantation.
<4 months

4-18 months

19-36 months

>36 months

Racial/Gender
Group

N

Mean
Rank

N

Mean
Rank

N

Mean
Rank

N

Mean
Rank

Caucasian
Male

94

104.44

94

111.99

89

106.72

90

102.03

Caucasian
Female

66

104.97

86

124.48

82

111.74

83

105.57

21

121.67

16

92.72

14

87.93

12

119.96

30

102.18

30

97.83

22

74.36

18

73.42

African
American
Male
African
American
Female

χ2=1.580
df=3
p=.664

χ2=5.815
df=3
p=.121
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χ2=7.948
df=3
p=.047

χ2=5.689
df=3
p=.128

100
90
80
70
60
50
40
30
20
10
0
<4 mo

4-18 mo

19-36 mo

Caucasian Male

Caucasian Female

African-American Male

African-American Female

>36 mo

Figure 4.1. Mean MCS Scores for Demographic Groups by Time Since Transplantation.
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100
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10
0
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19-36 mo

Caucasian Male
African-American Male

>36 mo

Caucasian Female
African-American Female

Figure 4.2. Mean PCS Scores for Demographic Groups by Time Since Transplantation.
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Table 4.3. Kruskal-Wallis Ranks and Test Statistics for Differences in Memphis Survey
Frequency Scores between Demographic Groups at <4 Months, 4-18 Months, 19-36
Months and >36 Months Post-Transplantation.
<4 months

4-18 months

19-36 months

>36 months

Racial/Gender
Group

N

Mean
Rank

N

Mean
Rank

N

Mean
Rank

N

Mean
Rank

Caucasian
Male

75

89.66

78

96.26

70

82.53

93

104.10

Caucasian
Female

49

107.37

65

98.40

65

90.35

88

113.09

27

68.85

19

95.11

16

83.88

15

70.73

34

98.84

33

102.98

22

93.59

16

117.75

African
American
Male
African
American
Female

χ2=9.714
df=3
p=.021

χ2=.385
df=3
p=.943

49

χ2=1.293
df=3
p=.731

χ2=6.796
df=3
p=.079

Table 4.4. Kruskal-Wallis Ranks and Test Statistics for Differences in Memphis Survey
Severity Scores between Demographic Groups at <4 Months, 4-18 Months, 19-36
Months and >36 Months Post-Transplantation.
<4 months

4-18 months

19-36 months

>36 months

Racial/Gender
Group

N

Mean
Rank

N

Mean
Rank

N

Mean
Rank

N

Mean
Rank

Caucasian
Male

71

82.68

77

97.49

65

79.75

90

98.82

Caucasian
Female

46

97.78

64

97.88

63

86.28

88

113.65

24

66.42

19

83.13

16

79.00

15

74.57

29

88.72

32

99.28

20

82.35

13

100.62

African
American
Male
African
American
Female

χ2=6.831
df=3
p=.077

χ2=1.244
df=3
p=.742

50

χ2=.704
df=3
p=.872

χ2=6.670
df=3
p=.083

100
90
80
70
60
50
40
30
20
10
0
<4 mo

4-19 mo

19-36 mo

Caucasian Male
African-American Male

>36 mo

Caucasian Female
African-American Female

Figure 4.3. Mean Memphis Survey Frequency Scores for Demographic Groups by Time
Since Transplantation.
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19-36 mo
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Caucasian Female
African-American Female

Figure 4.4. Mean Memphis Survey Severity Scores for Demographic Groups by Time
Since Transplantation.
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Figure 4.5. Time-Related Centile Range for Kidney Transplantation Recipients: SF-12 Health Survey.
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Figure 4.6. Time-Related Centile Range for Kidney Transplantation Recipients: Memphis Survey.
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Discussion
QoL life measurements such as those provided by the SF-12 and the Memphis
Survey are rarely used in the clinical setting to assess individual patients and no studies
have reported routine use in the kidney transplantation setting of any QoL outcome
measure. A number of reasons have been discussed as to why QoL outcomes are not used
in the clinical setting in spite of the importance placed on QoL (Higginson & Carr, 2001,
Greenhalgh, Long, & Flynn, 2005). Perhaps the most common reason is the perceived
time spent completing questionnaires that subsequently provide information that is
difficult to interpret and is perceived to offer little insight into an individual patient’s
status. The SF-12 and Memphis Survey are self-administered questionnaires that most
patients can complete without assistance in a short period of time prior to the clinic visit.
The time-related centile ranges place the scores in a context that can be easily interpreted
for patients as they compare their score with others and monitor their progress over time.
Espallagues, Valderas, and Alonso (2000), examined the influence the use of
health status measures had on clinical decision making and improvement in patient
outcomes. Although, the assessment of QoL did not have a direct influence on patient
outcomes or clinical decision making, this review concluded that using health status or
QoL measures modified the process of patient care. Greenhalgh, Long, & Flynn (2005)
support this conclusion suggesting that studies may not be asking the correct question in
evaluating the utility of patient outcomes in clinical practice and instead argue for a
theory driven approach to evaluation of the use of QoL measurement tools for patient
assessment that focuses on the process as well as the effect of QoL measures on decision
making or clinical outcomes. For example, QoL assessment has been used in the
oncology setting with beneficial results, not in patient outcomes per se but rather in
increased communication and heightened provider awareness of the patient’s QoL
(Detmar et al., 2002). Velikova et al. (2004) likewise found that routine assessment of
QoL of oncology patients enhanced patient-provider communication and in addition
correlated with improved QoL and emotional functioning. The time-related centile ranges
presented in this study for kidney transplant recipients would facilitate interpretation of
QoL scores, facilitate routine assessment of QoL outcomes, enhance discussions with
patients regarding their Qol outcomes, identify patients who would benefit from
interventions designed to improve QoL outcomes, and help or to reassure those patients
who are doing well.
The SF-12 has been used to estimate QoL for the general population. Mean scores
for the general population reported for the PCS and MCS score respectively are 49.6 and
52.0 (Johnson & Coons, 1998). Hathaway, et al. (2003b) reported the range of scores for
the US general population from 13-69 for the PCS and 10-70 on the MCS. Mean score
for this sample for PCS and MCS scores were 42.39 (range 6 to 65) and 50.11 (range 10
to 71) respectively. The mean and range of the MCS scores in this sample are comparable
to the general population. However, the PCS scores are were lower when compared to the
general population. This is consistent with early data reported from the PORTEL registry
and indicates impaired physical QoL following kidney transplantation (Hathaway, et al.
2003b).
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Time-related centile ranges are useful if the sample used for construction of the
range is representative of the population for which it is designed. The sample for this
study was drawn from a multi-institutional study with participants recruited from
different regions of the country. Since the participants were from diverse areas and
diverse transplantation centers, the ranges have greater generalizability than a sample
drawn from a single site.
The gender and racial distribution in this sample was compared to the distribution
reported in the United Network for Organ Sharing (UNOS) data base which represents all
transplant recipients. A significant difference was found between the UNOS data and the
PORTEL sample (χ2=25.03, p<.01). The percentage of Caucasian females in the study
sample was slightly higher than that reported in the UNOS database, 35.7% and 28.52%
respectively. This difference is likely to be of little clinical significance. African
American males, however, comprised only 9.5% of the study sample compared with
16.24% reported by UNOS. As a result application of the time-related centile ranges in
the African-American male population should be done cautiously and the ranges used
more as a means to monitor patient progress as opposed to comparison with an
established “norm”. Even so, the width of the individual centile ranges is such that if the
sample of African American males used in this study was different from the larger
population of African American male kidney transplant recipients, the impact of this
difference on the centile ranges and ultimate clinical use would be minimal.
African American and Causcasians were specifically targeted for this first effort
at establishing QoL centile ranges based on available data. Additional QoL data will be
required before centile ranges can be constructed or specific recommendations can be
made for use in other ethnic groups. Patients who have undergone more than one kidney
transplantation are also not represented in these time-related centile ranges. Just as using
QoL outcome measure has potential utility for kidney transplant recipients, recipients of
other solid organ transplantations may also benefit from QoL benchmarks to interpret
QoL outcome scores. The sample size required for development of time-related centile
ranges for other solid organ transplantation recipients may make development of the
ranges more challenging.
The PORTEL registry recruited participants from a variety of patient and site centric
venues. During the first half of the data collection period, participants were recruited
from transplantation centers, national transplantation meetings, community events,
support groups, and direct mail. This methodology had the potential to select a healthier
population that might not be fully representative of QoL following transplantation.
During the later data collection period recruitment was limited to referrals from
transplantation centers in order to create a more representative sample.
The time-related centile ranges constructed in this study do not account for patient
age which has been shown to be a factor in QoL post transplantation (Baiardi et al., 2002;
Fujisawa et al., 2000). The current sample includes transplant recipients between the ages
of 18 and 65, chosen to represent the working age adult. The decision to include all adults
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in the single time-related centile range was based primarily on the age distribution of the
participants in the sample.
Conclusion
The centile ranges constructed in this study have immediate clinical utility as a
tool for educating patients regarding expectations prior to transplantation and for
monitoring progress over time post transplantation. They can provide a means for
transplant recipients to compare their QoL to a reference range derived from a like
population as opposed to the general population and will serve as a catalyst for discussion
regarding interventions to enhance QoL.
The outcomes of this project also have application in the research arena as well.
QoL and changes in QoL will continue to be a variable of interest to researchers as the
kidney transplantation population ages. The outcomes of this study will provide
additional baseline data for future QoL research and can provide benchmarks for
evaluating interventions designed to improve QoL.
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Appendix A: Descriptive Statistics for Quality of Life Outcome Measures by
Racial and Gender Groups for Time Intervals Following Transplantation
Descriptive statistics, including the mean and median scores, standard deviation,
and range of the four QoL outcome variables for the 4 demographic groups (Caucasian
male, Caucasian Female, African American Male, and African American Female) at each
time interval post transplantation and bar graphs of the 50th percentile scores for each
outcome are provided in this appendix.
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Table A.1. Descriptive Statistics for the MCS Scores by Racial and Gender Groups for
Time Intervals Following Transplantation.
N

Mean

Median

Range

Standard
Deviation

94
66

51.71
51.42

53.21
53.35

52.07
49.38

10.34
9.98

21

52.99

52.04

27.36

7.46

30

50.10

50.22

31.74

8.30

94
86

54.45
50.74

54.78
54.15

52.95
50.87

11
10.46

16

47.41

44.57

30.55

10.09

30

50.52

51.08

33.27

9.58

89
82

48.33
49.84

50.04
51.54

45.88
54.97

10.78
10.62

14

50.53

53.88

34.39

10.74

22

49.53

49.36

25.55

8.64

90
83

48.34
48.28

50.28
51.46

58.22
47.98

11.68
10.87

12

51.15

56.14

42.91

13.15

18

47.67

48.43

34.95

11.30

4-18 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
4-18 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
19-36 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
>36 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female

68

100
90
80
70
60
50
40
30
20
10
0
<4 mo

4-18 mo

19-36 mo

Caucasian Male
African-American Male

>36 mo

Caucasian Female
African-American Female

Figure A.1. 50th Percentile, MCS Scores for Demographic Groups by Time Since
Transplantation
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Table A.2. Descriptive Statistics for the PCS Scores by Racial and Gender Groups for
Time Intervals Following Transplantation.
N

Mean

Median

Range

Standard
Deviation

94
66

36.06
36.59

36.02
34

46.01
47.15

11.3
11.66

21

39.20

40.36

38.33

10.95

30

36.27

34.47

45.07

11.32

94
86

44.09
46.07

45.71
47.96

59.29
54.24

12.15
12.5

16

41.77

40.36

32.5

9.43

30

41.38

43.04

47.09

13.13

89
82

44.83
45.99

47.98
50.15

51.62
52.34

13.05
12.7

14

40.94

41.13

42.9

13.48

22

38.15

38.42

44.96

13.1

90
83

44.36
44.79

48.46
47.9

45.23
52.98

12.34
12.15

12

48.08

48.32

38.29

11

18

39.43

39.72

36.45

9.47

<4 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
4-18 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
19-36 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
>36 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female

70

100
90
80
70
60
50
40
30
20
10
0
<4 mo

4-19 mo

19-36 mo

Caucasian Male
African-American Male

>36 mo

Caucasian Female
African-American Female

Figure A.2. 50th Percentile, PCS Scores for Demographic Groups by Time Since
Transplantation.
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Table A.3. Descriptive Statistics for the Memphis Survey Frequency Scores by Racial
and Gender Groups for Time Intervals Following Transplantation.
N

Mean

Median

Range

Standard
Deviation

75
49

43.52
49.63

40.93
50.5

111.97
96.96

25.91
22.92

27

32.98

27.58

85.84

23.2

34

45.75

43.92

70.16

20

78
65

49.93
52.1

45.13
46.61

131.36
132.62

29.64
31.86

19

48

42.38

80.60

21.15

33

52.2

50

92.00

23.21

70
65

53.81
59.29

45.67
57.97

133.46
142.14

33.47
35.04

16

52.31

43.

82.84

23

22

59.5

60.15

100.14

27.87

93
88

59.08
64.28

57.36
59.1

167.73
168.51

35.82
34.33

15

44.09

36.33

147.86

40.73

16

64.56

67.24

88.51

27.82

<4 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
4-18 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
19-36 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
>36 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female

72

100
90
80
70
60
50
40
30
20
10
0
<4 mo

4-19 mo

19-36 mo

Caucasian Male
African-American Male

>36 mo

Caucasian Female
African-American Female

Figure A.3. 50th Percentile, Memphis Survey Frequency Scores for Demographic Groups
by Time Since Transplantation.
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Table A.4. Descriptive Statistics for the Memphis Survey Severity Scores by Racial and
Gender Groups for Time Intervals Following Transplantation.
N

Mean

Median

Range

Standard
Deviation

71
46

35.32
41.53

29.83
42.73

29.83
106.75

27.6
25.23

24

26.59

15.42

83.12

24.38

29

35.28

32.94

69.18

19.28

77
64

45.37
48.03

41.38
38

133.18
135.17

30.91
36.33

19

36.66

34.55

98.57

25.41

32

45.18

38.73

109.33

26.74

65
63

46.67
52.53

40.3
49.46

113.28
132.21

33.68
37.15

16

44

32.55

82.90

25.54

47.03

40.95

116.75

31.83

90
88

52.92
59.95

43.31
53.64

183.64
172.14

41.7
37.15

15

40.46

27.81

149.68

43.54

13

47.21

58.25

68.61

23.27

<4 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
4-18 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female
19-36 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female

20

>36 months
Caucasian Male
Caucasian Female
African American
Male
African American
Female

74

100
90
80
70
60
50
40
30
20
10
0
<4 mo

4-19 mo

19-36 mo

Caucasian Male
African-American Male

>36 mo

Caucasian Female
African-American Female

Figure A.4. 50th Percentile, Memphis Survey Severity Scores for Demographic Groups
by Time Since Transplantation.
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Appendix B: Memphis Survey Subscales
The Memphis Survey was developed at the University of Tennessee Health
Science to assess frequency and severity of side effect from immunosuppressant
medications. The survey consists of 5 subscales to evaluate the areas that have been
reported to be most problematic for transplant recipients. The subscale scores are totaled
to provide a cumulative score for frequency and severity of side effects of
immunosuppressant therapy. Descriptive statistics for the subscales were reviewed for the
sample as a whole with all time groups combined by the racial and gender specific
demographic groups, Caucasian men, Caucasian women, African-American men and
African-American women. The means and ranges for the subscale scores were similar
(Tables B.1 and B.2) and were represented in the total frequency and severity scores. The
study aim was to design time-related centile ranges that would be useful in clinical
practice. Separate ranges for the 5 subscales which would be very similar to each other
and to the range for the total scores would be more unwieldy to implement in practice and
contribute little additional information. As a result the decision was made include only
the cumulative Memphis Survey frequency and severity scores in the analysis for this
study.
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Table B.1. Descriptive Statistics for the Memphis Survey Frequency Subscale Scores.
Subscale
Emotional
Burden

Life/Role
Responsibility

GI distress

Mobility

Miscellaneous

Racial-Gender
Group

N

Mean

Standard
Deviation

Min

Max

Caucasian Male
Caucasian Female
African-American
Male
African-American
Female
Total

395
336

10.38
10.66

8.50
8.34

0.00
0.00

40.00
39.09

78

7.45

6.19

0.00

28.18

108

10.33

6.82

0.00

25.45

917

10.23

8.12

0.00

40.00

Caucasian Male
Caucasian Female
African-American
Male
African-American
Female
Total

388
335

9.49
9.45

9.08
9.47

0.00
0.00

39.09
40.00

78

8.1

9.19

0.00

36.36

106

9.95

8.45

0.00

34.55

907

9.41

9.16

0.00

40.00

Caucasian Male
Caucasian Female
African-American
Male
African-American
Female
Total

394
338

7.15
9.21

6.67
7.27

0.00
0.00

28.33
35.00

77

7.03

6.06

0.00

28.33

109

8.36

6.18

0.00

26.27

918

8.04

6.86

0.00

35.00

Caucasian Male
Caucasian Female
African-American
Male
African-American
Female
Total

327
270

12.94
14.50

6.83
6.97

0.00
0.00

37.27
32.73

78

10.16

6.02

0.00

25.45

110

11.67

5.58

0.00

25.45

785

13.02

6.77

0.00

37.27

Caucasian Male
Caucasian Female
African-American
Male
African-American
Female
Total

393
338

11.86
13.13

9.89
10.59

0.00
0.00

40.00
40.00

78

9.87

8.64

0.00

40.00

109

13.25

8.96

0.00

38.57

918

12.33

9.98

0.00

40.00

77

Table B.2. Descriptive Statistics for the Memphis Survey Severity Subscale Scores.
Subscale
Emotional
Burden

Life/Role
Responsibility

GI distress

Mobility

Miscellaneous

Racial-Gender
Group

N

Mean

Standard
Deviation

Min

Max

390
335

9.33
9.74

9.14
9.05

0.00
0.00

40.00
40.00

77

5.75

6.55

0.00

28.18

103

7.73

7.11

0.00

32.73

905

9.00

8.76

0.00

40.00

Caucasian Male
Caucasian Female
African-American
Male
African-American
Female
Total

382
332

8.08
8.51

8.71
9.38

0.00
0.00

40.00
40.00

77

6.59

9.05

0.00

36.36

101

7.06

7.44

0.00

28.18

892

8.00

8.87

0.00

40.00

Caucasian Male
Caucasian Female
African-American
Male
African-American
Female
Total

389
333

6.31
8.18

7.24
7.73

0.00
0.00

30.00
35.00

76

6.05

6.19

0.00

28.33

105

6.49

5.74

0.00

21.67

903

7.00

7.24

0.00

35.00

Caucasian Male
Caucasian Female
African-American
Male
African-American
Female
Total

388
334

11.16
12.63

10.31
11.25

0.00
0.00

40.00
40.00

77

90.5

8.91

0.00

40.00

101

11.71

9.63

0.00

38.57

900

11.59

10.52

0.00

40.00

Caucasian Male
Caucasian Female
African-American
Male
African-American
Female
Total

318
268

10.36
12.37

7.21
7.61

0.00
0.00

36.36
32.73

77

7.49

6.16

0.00

27.27

105

8.95

6.45

0.00

32.73

768

10.58

7.32

0.00

36.36

Caucasian Male
Caucasian Female
African-American
Male
African-American
Female
Total
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